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Fertility is the natural human capability of producing offspring. For men, ferti-
lity is, first of all, having sperm that can fertilize an egg. It has been suggested 
that sperm counts are declining over the last decades and that these changes 
might be responsible for a possible decline in fertility rates in the industrialized 
world. Carlsen and colleagues, in 1992, were the first to show that semen qua-
lity had worsened during the 20th century. The review of 61 papers from 1938 
to 1990 documented a significant decrease in mean sperm count and in seminal 
volume (Carlsen et al., 1992). Furthermore, a recent meta-analysis confirmed 
the decline in sperm counts between 1973 and 2011 (Levine et al., 2017). The 
overall decline in fertility is possibly related to nutrition, lifestyle, enviromental 
factors, stress level and a variety of other things. Infertility is a worldwide 
problem, defined by the WHO as the inability of a couple to achieve conception 
or bring a pregnancy to term after 12 months or more of regular unprotected 
sexual intercourse (WHO, 2010). In the diagnosis and management of inferti-
lity, the fertility status of both partners must be considered, because this might 
determine the final outcome (Jungwirth et al., 2015). It has been proposed that 
infertility affecs 15% of couples who do not achieve pregnancy within one year 
and seek medical treatment for infertility (Thonneau et al., 1991; Sharlip et al., 
2002). No absolutely firm data are available for Estonia but considering the 
above-mentioned prevalence, infertility problems might affect up to 15–20 000 
families that cannot have a child naturally. Besides, at least 30 million men 
worldwide are infertile with the highest rates in Africa and Eastern Europe 
(Agarwal et al., 2015). Male infertility may be a consequence of congenital or 
acquired urogenital abnormalities but the common type is idiopathic infertility 
with no identifiable cause (Jungwirth et al., 2015). The calculated region-
specific data shows that in 20–70 % of cases, a male-infertility-associated factor 
is found (Agarwal et al., 2015).  
An increase in male infertility worldwide coincides with male obesity in 
reproductive-age men which has nearly tripled in the past 30 years (Palmer et 
al., 2012). In the 21st Century, obesity has become an epidemic and is one of 
the greatest public health challenges. Worldwide obesity has more than doubled 
since 1980. In 2016, more than 1.9 billion adults, 18 years and older, were 
overweight. Of these over 650 million were obese (WHO, 2016).  
Data regarding male adiposity shows that in the Estonia, 59.9 % of men are 
classified as overweight. Of these, 19.8 % are obese, with a body mass index 
above 30 kg/m2 (Tekkel M, 2017). Increased body weight has been associated 
with number of adverse health consequences including infertility (Guh et al., 
2009; Pasquali et al., 2007). It has been proposed that men with excess body 
weight are at increased risk of infertility according to the dose-response 
relationship between increasing BMI and subfecundity (Nguyen et al. 2007; 
Ramlau-Hansen et al., 2007). Obesity can affect fertility by causing also 
hormonal imbalances. In the prospective Massachusetts Male Aging Study, 
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moving from a non-obese to an obese state resulted in a decline of testosterone 
levels comparable to that of advancing 10 years in age (Travison et al., 2007). 
At the same time, obesity is an important modifiable risk factor for a number of 
diseases. Measures can therefore be taken to reverse both the unhealthy con-
sequences associated with obesity and its negative impact on male fertility. 
(Cabler, et al, 2010; Du Plessis et al., 2014). However, many factors contribute 
to the decline in human fertility and the mechanisms linking obesity and 
adverse reproductive function are still being explored. 
The aim of the current thesis was to specify the relationships between body 
composition, obesity-related disorders, lifestyle and male reproductive para-
meters. 





4. REVIEW OF THE LITERATURE 
4.1. Anatomy and physiology of the male  
reproductive system  
4.1.1. The male reproductive organs and spermatogenesis 
The male reproductive system consists of several organs acting together to pro-
duce functional spermatozoa, and to deliver these spermatozoa to the female 
reproductive tract.  
The primary reproductive organs, testicles are located outside the body cavi-
ty in the scrotum and contain seminiferous tubules surrounded by tunica albu-
ginea and hormone-producing Leydig cells as interstices between the tubules. 
According to available data the optimal testicular volume ranges for normal 
testicular function vary within wide limits, remaining between 14-35 ml, mea-
sured with orchidometer (Takihara et al., 1983; Jørgensen et al., 2002; Saka-
moto et al., 2008; Stewart et al., 2009; Nieschlag et al., 2010; Andrology 
Australia, 2014). The testis is the site of spermatogenesis and also the site of 
androgen synthesis and secretion. Comparing the two ethnic subgroups of 
young men from Estonia, ethnic Russians have higher median testis size [26 ml 
(25th–75th: 23–29)] than Estonians [23 ml (25th–75th: 20–25)] (Erenpreiss et 
al., 2017). However, with respect to male reproductive health, a critical total 
testicular volume (TTV) that would ensure adequate reproductive function has 
not been formally established.  
The adult male reproductive anatomy includes also epididymis, ductus defe-
renses, seminal vesicles, bulbourethral (Cowperʼs) glands, prostate gland, and 
penis.  
Spermatozoa, the haploid germ cells, are produced in the testis and undergo 
maturational changes as they transit the epididymis. Spermatogenesis starts with 
stem cells division and ends with the maturation of sperm cells, including 
mitotic proliferation, meiotic division and transformation of haploid germ cells 
(spermatids) into sperms. The vas deferens transports the spermatozoa from the 
epididymis to the ejaculatory duct in the prostate. The spermatozoa and secre-
tions of the seminal vesicles empty together, with secretions from the prostate, 
into the prostatic urethra. Secretions from the bulbourethral gland contribute to 
the ejaculate as the mixture exits the body through the penile urethra (Seeley et 
al., 1999; Nieschlag et al., 2010; Robaire  & Chan, 2010). 
 
 
4.1.2. Endocrine and nervous control of  
the male reproductive tract  
The entire male reproductive system is maintained by pituitary gonadotropins 
and androgens secreted by the testis. The anterior pituitary produces the 
gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone 
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(LH), under the control of the hypothalamic gonado- tropin-releasing hormone 
(GnRH). GnRH secretion is in turn under the control of the kisspeptin-GPR54 
(metastin) system. FSH is required for the initiation of spermatogenesis, and LH 
stimulates androgen production by the testicular Leydig cells. The testis re-
quires high concentrations of testosterone to maintain the process of spermato-
genesis and the accessory organs are dependent on androgen for proper secre-
tory function. Testosterone is a precursor of two important hormones: through 
5α-reduction it gives rise to the highly biologically active hormone 5a-dihydro-
testosterone, and through aromatization to estradiol. Estrogens influence testo-
sterone effects by acting either synergistically or antagonistically. Steroids in 
the circulation exist as free or bound to extracellular proteins such as sex hor-
mone binding globulin (SHBG), androgen binding protein and/or albumin. In 
addition to hormonal control, the reproductive organs are also subject to sym-
pathetic and parasympathetic nervous control. The ejaculation is under sym-
pathetic and erectile function of the penis is under parasympathetic control. 
(Nieschlag et al., 2010; Robaire  & Chan, 2010). 
 
 
4.2. Semen quality as a marker of  
male reproductive function 
Semen analysis is a panel of tests performed for evaluation of male reproductive 
function. The World Health Organization has developed a manual for the 
evaluation of semen which includes the physical appearance of the ejaculate, 
assessments of sperm count, motility, vitality, morphology, and functional as-
pects of the sperm and semen sample (Cooper et al., 2009; WHO, 2010). The 
proposed lower reference limits (5th percentile) for semen parameters are 
described in Table 1. 
 
 
Table 1. Lower reference limits (5th centiles and their 95% Confidence Intervals) for 
main semen characteristics (WHO, 2010). 
Parameter  Lower reference limit (CI) 
Semen volume (mL) 1.5 (1.4–1.7) 
Total sperm number (106/ejaculate) 39 (33–46) 
Sperm concentration (106/mL) 15 (12–16) 
Total motility (%) 40 (38–42) 
Progressive motility (%) 32 (31–34) 





Semen analysis actually shows the functions of many male reproductive organs 
and glands as it consists of spermatozoa mixed with secretions from the testis, 
epididymis, prostate gland and seminal vesicles (Robaire & Chan, 2010). 
Recommended reference values for semen parameters are not the minimum 
values to define infertility, as men with semen variables outside these reference 
ranges may be fertile (Sikka & Hellstrom, 2016). Therefore, if the results of 
semen analysis are normal, according to WHO criteria, then one test is con-
sidered sufficient to determine male seminal function. If the results are ab-
normal in at least two tests, further andrological investigations are indicated 
(Jungwirth et al., 2015). There are fluctuations in semen parameters from day to 
day. Because the volume of the seminal fluid may be quite variable, it has been 
suggested that total sperm number per ejaculate provides a more accurate 
assessment of testicular function than does sperm concentration, providing 
information about the testis and the accessory glands (Nieschlag et al., 2010; 
Robaire & Chan, 2010; WHO, 2010). Comparing the two ethnic subgroups of 
young men from Estonia, ethnic Estonians have higher median total sperm 
counts [235 × 106/ml (25th–75th: 117–380)] than Russians [208 × 106/ml (25th–
75th: 106–340)] (Erenpreiss et al., 2017).  
It is important to differentiate between the following: oligozoospermia 
(spermatozoa <15 million/mL), asthenozoospermia (<32% progressive motile 
spermatozoa) and teratozoospermia (<4% normal forms) (WHO 2010; Jung-
wirth et al., 2015). 
The quality of semen analysis varies depending on how and where it is col-
lected and on the analytical methods employed. There are also factors that 
usually cannot be modified, such as sperm production by the testicles, secre-
tions of male accessory glands and recent (particularly febrile) illness, as well as 
other factors, such as abstinence time before the semen analysis, that should be 
recorded and taken into account in the interpretation of results. Semen quality 
also depends on the size of the testicles. Several studies have shown a positive 
correlation between male fertility parameters and testicular volume (Sakamoto 
et al, 2008a; Bahk et al., 2010; Tijani et al, 2014; Ventimiglia et al., 2016). 
 
 
4.3. Male factor infertility: diagnostic classification, 
epidemiology and aetiology 
Male infertility may be the symptom of a wide range of disorders and can be 
classified according to the topographic principle or according to the nature of 
the cause. However, in many clinics the diagnosis of male infertility still relies 
solely upon the findings of semen analysis. A scheme for the diagnostic classi-
fication of an infertile coupleʼs male partner has been suggested by WHO al-
ready a quarter century ago (Rowe et al 1993). This scheme, incorporating the 
results of semen analysis, clinical examination and hormonal tests, serves as a 
basis for standardization. According to the recent EAU guidelines, andrological 
investigations are indicated if semen analysis is abnormal in at least two tests to 
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define a diagnosis (Jungwirth et al., 2015, 2017). Based on the results obtained, 
additional tests and procedures may be recommended, including serial semen 
analyses, endocrine evaluation, post-ejaculatory urinalysis, ultrasonography, 
specialized tests on semen and sperm, and genetic screening (Pfeifer et al., 
2015; Jungwirth et al., 2015, 2017). 
A reduction in the male fertility potential may be due to congenital or 
acquired conditions such as urogenital abnormalities, urogenital tract infections, 
increased scrotal temperature (e.g. as a consequence of varicocele), genetic ab-
normalities, endocrine disturbances, testicular failure, immunologic problems, 
malignancies, systemic diseases, altered lifestyle, and exposure to gonadotoxic 
factors (Nieschlag et al., 2010; Jungwirth et al., 2015).  
The study of Agarwal et al. showed that the percentage of infertile men 
ranged from 2.5% to 12%. Male infertility rates were highest in Africa and 
Central/Eastern Europe, whereas corresponding rates for North America, 
Australia, and Central and Eastern Europe varied from 4.5–6%, 9%, and 8–
12%, respectively (Agarwal et al., 2015). 
Due to the relative nature of both male and female infertility, it is difficult to 
define the exact distribution of the causes of fertility, particularly of disturbed 
male fertility. Males are thought to be solely responsible for 20–30% of inferti-
lity cases but contribute to 50% of cases overall. The WHO carried out a multi-
center study in 33 centers worldwide involving 7273 infertile couples and found 
that in 20% of the cases the problem was predominantly in the male, in 39% the 
problem was predominantly in the female, in 26% abnormalities were found in 
both partners, and in the remaining 15% no clear-cut cause of infertility was 
identified (WHO, 1987). A survey carried out among 1686 couples having con-
sulted a gynecologist for an infertility problem detected that in 38% of the cases 
abnormalities were found in both partners, in 34% of the cases the problem was 
predominantly in the female and 20% of the cases the problem was pre-
dominantly in the male. In that study the origin of couple infertility was not 
found in 8% of the cases (Thonneau et al., 1991). In addition, Agarwal et al. 
revealed that the distribution of infertility due to male factors ranges from 20% 
to 70% (Agarwal et al., 2015). 
The cause of fertility impairment cannot be determined in several cases. Part 
of patients are having a defect in spermatogenesis of which the underlying 
causes (including genetic ones) remain largely unknown. The only genetic tests 
routinely used in the diagnosis of male infertility are the analyses for the pre-
sence of Yq microdeletions and/or chromosomal abnormalities. Various other 
single gene or polygenic defects have been proposed to be involved in male 
fertility. Yet, their causative effect often remains to be proven.  
There are several other factors having the potential to influence male fertility 
such as advanced age, environmental exposures, smoking, drug and alcohol 
abuse and obesity.  
Considering all these factors, we can conclude that the topic is controversial 
and we still lack a definite answer regarding their role in determining male 
(in)fertility.  
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4.4. Male body type and surrogate measures of adiposity 
4.4.1. Male body type 
It is a well-known fact that there exist two type of fat deposition: male (android 
or apple type) and female (gynoid or pear type) pattern. Accordingly, men com-
pared to women have a larger visceral fat depot and they tend to deposit excess 
fat more in the abdominal region (Palmer & Clegg, 2015). The scientific 
explanations for the difference in body fat distribution between men and women 
are largely unknown. From a teleologic standpoint, it has been hypothesized 
that prehistoric man surviving through hunting and quick escape would need an 
effectively mobilizable energy source thus explaining the predilection for fat 
storage in the visceral depot due to the fact that visceral fat is more meta-
bolically active and easier to lose (Arner, 1997; Palmer & Clegg, 2015). A 
healthy body fat range for men is roughly 9-25 %, depending on the age and 
ethnicity (Gallagher et al., 2000; Hausman et al., 2001; Ho-Pham et al., 2011). 
A typical western, mostly sedentary lifestyle combined with energy-excess diet 
and frequently excessive alcohol use favor fat storage. Above the normal range 
of fat deposition, specially visceral fat, will be a source of proinflammatory 
cytokines and large amounts of free fatty acids that contribute to insulin resis-
tance and other features of the metabolic syndrome (Fain et al, 2004; Blüher, 
2013). Women, with higher levels of subcutaneous fat, are protected from 
diseases associated with obesity whereas men, with higher amounts of visceral 
fat deposition, are at increased risk for diseases associated with obesity (Palmer 
& Clegg, 2015). 
 
4.4.2. Surrogate measures of adiposity 
BMI as a surrogate measure of body fat is the standard system for classifying 
obesity at a population level. There are four categories of BMI ranges: under-
weight (BMI<18.5 kg/m2), normal weight (18.5-25 kg/m2), overweight (25–
29.9 kg/m2), obese (≥30 kg/m2) (WHO, 2000). At the same time validity of BMI 
to distinguish variability in body composition and body fat distribution, have 
been questioned (MacDonald et al., 2010). A problem with this method is that 
individuals with a high BMI may be mesomorphic and have a high amount of 
muscle mass (Cabler, et al, 2010). There are also metabolically obese, normal-
weight people who have normal BMI values but who suffer from metabolic 
complications commonly found in obese (Ruderman & Schneider, 1981). 
Therefore, BMI may not be the most accurate marker for total body fat per-
centage (BF%) and an even less suitable tool to assess body fat distribution. 
There are more accurate surrogate measures of adiposity. First of them is waist 
circumference (WC). Based on the International Diabetes Federation and WHO 
definition for Europid men three categories of WC exist: WC<94 cm (low risk), 
WC 94-101.9 cm (increased risk), WC ≥102 cm (high risk) (Alberti et al., 
2009). Second parameter is waist-to-height ratio (WHtR). The systematic 
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review recommend the use of the boundary value of 0.5 for WHtR supporting 
the simple public health message “keep your waist circumference to less than 
half your height” (Browning et al, 2010). A recent study shows that WHtR ≥ 0.5 
indicate early health risk and men are more likely than women to fall into this 
early ‘increased’ risk category, probably because of their greater propensity to 
central obesity (Ashwell & Gibson, 2016). Some years ago published meta-
analysis has demonstrated that WHtR is statistically superior to WC as well as 
being superior to BMI in the discrimination of cardiometabolic risk (Ashwell et 
al., 2012). In addition, bioelectrical impedance analysis (BIA) is a frequently 
used method for estimating body composition. Unfortunately, no accepted pub-
lished BF% ranges exist and evidence-based cut-off points for BF% are needed, 
as exist for BMI (Gallagher et al., 2000; Ho-Pham et al., 2011). 
 
4.5. Lifestyle-related factors associated with  
male reproductive health 
There are several factors that can lead to infertility in men. Although certain 
causes of male infertility cannot be changed, some causes of can be corrected. 
Even if at present, there exists no consensus about the effects of common life-
style factors on male fertility, some of them seem to be more detrimental, such 
as smoking, alcohol consumption and obesity.  
 
 
4.5.1. Effects of cigarette smoking on male fertility 
Cigarette smoke contains a large number of substances which are recognized as 
carcinogens and mutagens. Although the effect of cigarette smoking on sperm 
function has been reported, the mechanisms by which tobacco smoke affects 
male fertility parameters are not fully understood. Smoking is associated with 
lower seminal vesicles volume (Lotti et al., 2015), can affect semen quality 
(Ramlau-Hansen et al., 2007; Joo et al., 2012; Lee et al., 2014; Lotti et al., 
2015; Erenpreiss et al., 2017) and cause DNA damage (Anifandis et al., 2014). 
A positive, dose–response relationship between smoking, testosterone, LH and 
the LH/free testosterone ratios have been found (Ramlau-Hansen et al., 2007; 
Wang et al., 2013). It appears that the effects of cigarette smoking on testo-





4.5.2. Obesity related changes in  
male reproductive system 
4.5.2.1. The surrogate measures of adiposity in  
relation to semen quality  
Several reports have shown an inverse correlation between BMI and sperm 
parameters (Jensen et al., 2004; Hammoud et al., 2008; Hofny et al., 2010, 
Paasch et al., 2010, Leisegang 2014; Bieniek et al., 2016; Taha et al., 2016) and 
recent meta-analysis concluded that there is a relationship between BMI and 
sperm quality (Guo et al., 2017). Moreover, proportions of overweight (or 
obese) patients are significantly increased in groups of patients with azoo- and 
oligozoospermia (Punab et al., 2017). Also meta-analysis published in 2012 
showed that overweight and obesity are associated with an increased prevalence 
of azoospermia or oligozoospermia (Sermondade et al., 2012). In addition, 
some researches have reported that WC is inversely related to semen volume 
(Fejes et al., 2005, Hammiche et al., 2012; Eisenberg et al., 2014), sperm 
motility (Fejes et al., 2005, Hammiche et al., 2012) and sperm concentration 
(Hammiche et al., 2012, Leisegang 2014). Tsao CW et al. (2015) showed that 
increased adiposity (valued by BMI, WC, WHR, WHtR and BF%) was 
significantly negatively correlated with sperm concentration and normal sperm 
morphology (Tsao CW et al. 2015). Concurrently, other reports have failed to 
document association between BMI and sperm parameters (Aggerholm et al, 
2008; Li et al., 2009; Duits et al., 2010, MacDonald, 2013) and meta-analysis 
published in 2010 concluded that there is no evidence of an association between 
BMI and semen parameters (MacDonald et al., 2010). Further, Lu JC et al. 
(2014) indicated that obesity-associated markers (BMI, WC, WHR, WHtR) 
could not predict male semen quality (Lu JC, 2014). To recap, these findings 
suggest that the impact of male obesity on sperm quality rest controversial and 
the effects of male obesity on fertility are likely multifactorial (Palmer et al, 
2012; McPherson & Lane, 2015). 
 
 
4.5.2.2. The surrogate measures of adiposity in relation to 
reproductive hormone levels 
Deviations from normal body weight disturb the endocrine system. According 
to many researches (Jensen et al., 2004; Fejes et al., 2005; Aggerholm et al., 
2008; Wu et al., 2008; Chavarro et al., 2010; Rohrmann et al., 2011 MacDonald 
et al., 2013; Lu JC, 2014; Beaver et al., 2006) and systematic review with meta-
analysis (MacDonald et al., 2010), there is strong evidence that BMI, WC and 
WHtR are negatively associated with testosterone and SHBG levels. In recent 
years the results of some studies have put into question the long lasting concept 
of inhibitory effect of hyperinsulinemia on SHBG production and supported the 
concept that proinflammatory cytokines downregulate SHBG (Simo R, 2012 
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and 2015). Furthermore, BMI may be positively associated with plasma con-
centration of estrogens (Kley et al., 1980; Jensen et al., 2004; Chavarro et al., 
2010; Rohrmann et al., 2011). It has been proposed that elevated estrogen con-
centrations may result from an increased conversion of androgens to estrogens 
by adipose tissue produced aromatase in cases of weight gain (Palmer et al., 
2012). Spermatogenesis is under control of gonadotropins but it remains unclear 
if obesity has an impact on these parameters. Majority of the studies have not 
found relation between adiposity and gonadotropin levels (Jensen et al., 2004; 
Fejes et al., 2005; Aggerholm et al., 2008; Chavarro et al., 2010). It has been 
suggested that many factors could alter hypothalamic-pituitary-gonadal (HPG) 
axis functioning such as elevated oestrogen concentration (Schneider et al., 
1979; Kley et al., 1980), insulin functioning (Salvi et al., 2006), obesity-related 
cytokines secretion (Fui et al., 2014) and thereby affect male fertility potential. 
The main associations of hormonal mechanisms by which adiposity affects 




Figure 1. The role of adiposity and potential mechanisms of hormones that may affect 
male fertility. Weight gain is linked to insulin dysfunction and proinflammatory cyto-
kine production which are potent inhibitors of sex hormone-binding globulin (SHBG) 
production. Low levels of SHBG are negatively correlated to testosterone levels. The 
relationship between weight gain and testosterone is complex as low testosterone is both 
a cause and consequence of adiposity and low testosterone can affect fertility. Adiposity 
can be also considered a condition of increased aromatization of androgens to oestrogen 
by adipose tissue. Spermatogenesis is under control of gonadotropins and it has been 
suggested that elevated oestrogen concentration, insulin functioning and obesity-related 
cytokines secretion could alter hypothalamic-pituitary-gonadal (HT-P-G) axis func-





4.5.3. Alcohol consumption related changes in male 
reproductive system 
When alcohol is added directly to sperm, at concentrations equivalent to those 
in serum after moderate and heavy drinking, damaging effects are observed in 
both sperm motility and morphology (Donnelly et al., 1999). Alcohol consump-
tion is associated with increased numbers of morphologically abnormal sperm 
(Joo et al., 2012) and it has been reported that already modest habitual alcohol 
consumption of more than 5 units per week had adverse effects on semen 
quality (Jensen et alb., 2014). Also the duration of endocrinological recovery 
after drinking is a quite long-lasting process and the normal glandular-pituitary 
feed-back processes may be partly put out of order (Ruusa et al., 1997). It has 
been shown that compared with non-drinkers current drinkers with increasing 
recent alcohol intake have lower concentrations of SHBG and possibly higher 
testosterone and free testosterone levels (Shiels et al., 2010; Jensenc et al., 
2014). At the same time, some other researchers show that alcohol abuse is 
associated with increased FSH, LH, and estrogen levels and decreased testo-
sterone levels (Muthusami & Chinnaswamy, 2005). Furthermore, men who 
drink more alcohol also smoke more (Anifandis et al., 2014; Jensen et alc., 
2014). Besides, in current western societies alcohol and obesity-related health 




4.6. Obesity, alcohol consumption and liver injury 
The liver, body’s second largest organ, plays a central role in metabolic 
processes. According to epidemiological studies the main cause of liver injury 
remains alcohol (O’Shea, et al., 2010; Blachier et al., 2013). Even moderate 
drinking may lead to significant liver enzymes elevations (Danielsson, 2014). 
Obesity, particularly visceral obesity, can also lead to liver damage. In over-
weight and obese patients, liver tests, especially alanine aminotransferase 
(ALT) and gamma-glutamyl transferase (GGT), are associated positively with 
BMI, WC and visceral fat mass. (Burns et al., 1996; Adams et al., 2008; 
Verrijken et al., 2010; Danielsson et al., 2014). With increasing BMI the effect 
of moderate alcohol consumption on liver enzymes increases too (Alatalo et al., 
2008). Recent studies have shown that serum liver enzymes activity is as-
sociated not only with liver injury but also with many cardiovascular disease 
risk factors and could predict new-onset type 2 diabetes, hypertension, stroke 
and myocardial infarction (Findeisen et al., 2007; Gomez-Samano et al., 2012; 
Onat et al., 2012; Labayen et al., 2014).  
In addition, liver enzyme levels could be used as clinical predictors of meta-
bolic syndrome (Zhang, et al., 2015). 
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Still, the data on associations of liver enzymes and incidence of male repro-
ductive health does not exist. 
 
 
4.7. Metabolic syndrome 
4.7.1. Classification of metabolic syndrome  
Metabolic syndrome (MS) is a complex of medical conditions characterized by 
abdominal obesity, dyslipidemia, hypertension and high fasting glucose. In the 
1988 Banting Lecture, Reaven used the term syndrome X to refer to the ten-
dency of glucose intolerance, hypertension, low high density lipoprotein (HDL) 
cholesterol and raised triglycerides, and hyperinsulinaemia to occur in the same 
individual (Reaven, 1988). Abdominal obesity was not included in Reavenʼs 
original description but he suggested that avoiding obesity would protect 
against insulin resistance. In 1998, the first definition of the MS was formulated 
by the WHO, which proposed that MS may be defined by the presence of insu-
lin resistance or its surrogates, impaired glucose tolerance or diabetes type 2 
combined with at least 2 other factors (hypertension, increased level of blood 
lipids, obesity and microalbuminuria) (WHO, 1999). Thereafter, various diag-
nostic criteria of MS have been proposed by different organizations. One of the 
most widely used criteria of MS is The National Cholesterol Education Pro-
gram’s Adult Treatment Panel III (ATP III) report which identified the MS as a 
multiplex risk factor for cardiovascular disease (Grundy et al., 2004). MS is 
diagnosed when a patient has at least 3 of the following 5 conditions: abdominal 
obesity, elevated triglyceride, reduced HDL cholesterol, elevated blood pressure 
and elevated fasting glucose. ATP III criteria did not require demonstration of 
insulin resistance per se. To address variation between professional guidelines, 
the National Heart, Lung, and Blood Institute (NHLBI), the American Heart 
Association (AHA), International Diabetes Foundation (IDF) and others have 
proposed a harmonized definition of MS. It was agreed that there should not be 
an obligatory component, but that waist measurement would continue to be a 
useful preliminary screening tool (Alberti et al., 2009). A link between MS and 
lower general health status of men has also been proved (Lakka HM, et al., 
2002; Lotti et al., 2013; Ventimiglia et al., 2016).  
 
 
4.7.2. Metabolic syndrome related changes in  
male reproductive system 
The worldwide prevalence of MS emerged not only as a predictor of cardio-
vascular disease but also as a potential contributing factor to male infertility. 
There is strong evidence that MS is negatively associated with testosterone 
levels (Corona et al., 2006; Lotti et al., 2013; Ventimiglia et al., 2016a,b) and 
might be positively related with plasma concentration of estrogen (Maggio et 
al., 2010). Even if MS and the testosterone deficiency in men are closely linked 
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then the effect of MS on male semen quality has not been sufficiently inves-
tigated on the basis of available data. There are some studies which have 
concluded that MS may affect male semen parameters (Lotti et al., 2013; 
Leisegang et al., 2014) et al; Ventimiglia et al., 2016b; Elsamanoudy et al., 




5. STUDY RATIONALE AND AIMS OF THE RESEARCH 
There are several unanswered questions concerning the factors that influence 
reproductive function in men and the prevalence of obesity and MS has not 
previously been studied in the context of male infertility in Estonia. Further-
more, the associations between obesity, MS, alcohol consumption and male 
infertility remain controversial. Most previous studies on male obesity, MS and 
infertility based mainly on BMI, which is an inaccurate measure of body fat 
content and does not take into account muscle mass. Data on liver tests and 
reproductive parameters is so far rather limited. 
The general aim of this work was to investigate the eventual role of body 
composition, obesity and obesity-related health and lifestyle conditions in male 
infertility assessing their relationship with semen and hormonal parameters in a 
group of provenly fertile men and male partners of infertile couples.  
The specific aims of the research were: 
1 .  To estimate the prevalence and characteristics related to adiposity and MS in 
a group of provenly fertile men and male partners of infertile couples. 
2 .  To investigate the associations of different surrogate measures of adiposity 
and MS with basic semen analysis parameters in a group of provenly fertile 
men men and male partners of infertile couples. 
3 .  To investigate the associations of different surrogate measures of adiposity 
and MS with serum levels of reproductive hormones in a group of provenly 
fertile men and male partners of infertile couples. 
4 .  To elucidate which are the best surrogate markers of body composition 
showing most clearly the relationship between adiposity, semen characte-
ristics and reproductive hormone levels. 
5 .  To examine the relationship between liver tests (GGT, ALT), basic semen 
parameters and serum levels of reproductive hormones in a group of pro-
venly fertile men.  
6 .  To examine the relationship between alcohol consumption, body composi-




























6.1.1. Male partners of pregnant women 
A cross-sectional, multicentre study was conducted during the period 2010 – 
2011. 3175 pregnant women who presented for prenatal care at Tartu University 
Womenʼs Clinic and West-Tallinn Central Hospital Womenʼs Clinic got in-
formed about this study and their partners were invited to participate. Approxi-
mately 30% of eligible men agreed to participate. The participants as fertile men 
(FM) had a choice complete only a questionnaire or in addition to filling out a 
questionnaire to also pass a physical examination and give blood tests and/or 
semen analysis. A total 277 men (30 % of participants), who were 21 to 57 
years of age, agreed to give semen and blood samples, complete a questionnaire 
and pass a physical examination. The flow chart (Figure 2) shows the number of 
subjects recruited and finally included in the studies. Inclusion and exclusion 
criteria for participants have been described more in detail elsewhere (Paper 1, 
2, 4).  
In addition, all pregnant partners of liver enzymes and semen quality study’s 
participants were tested for hepatitis B, C and only the men whose partners had 
negative tests were included (Paper 2). 
 
 
6.1.1.1. The study of reproductive parameters in  
relation to adiposity among fertile men 
260 men were categorized into 3 BMI groups: (I) <25 kg/m2, (II) 25–29.9 kg/m2, 
(III) ≥30 kg/m2 (WHO, 2000). There were no men categorized as underweight 
(BMI <18.5 kg/m2) in study group. Men were also divided into 3 groups 
according to their WC: (I) <94 cm (low risk), (II) 94–101.9 cm (increased risk), 
(III) ≥102 cm (high risk). These groups were formed based on the International 
Diabetes Federation and WHO definition for Europid men (Alberti et al., 2009). 
According to WHtR, high- and low risk group was formed on the basis of the 
suggested cut off point: (I) <0.5; (II) ≥0.5 (Ashwell et al., 2012).  
Additionally, we calculated percentiles for BMI [(25th) 23 kg/m2, (50th) 
25.2 kg/m2, (75th) 28.3 kg/m2], BF% [(25th) 15.7%, (50th) 19.6%, (75th) 
23.4%], WC [(25th) 84.0 cm, (50th) 90.0 cm, (75th) 98.0 cm] and WHtR 
[(25th) 0.463, (50th) 0.497, (75th) 0.540]. Thereafter, we categorized men into 
quartiles of BMI, BF%, WC and WHtR to explore association between different 
surrogate measures of adiposity, semen parameters and sex hormones in more 
detail.  
To determine the differences in semen and blood tests parameters according 
to BMI, BF%, WC and WHtR groups, we took into account known potential 
confounding factors. In the semen analysis we included study age, sexual absti-
nence time, smoking and alcohol consumption. In the analysis of blood 
samples, we controlled for study age, smoking and alcohol consumption. 
 
26 
6.1.1.2. The study of liver tests and alcohol consumption in relation 
to obesity and reproductive parameters among fertile men 
Men were categorized into 3 BMI groups (Table 1, Paper 2) and 3 groups 
according to their WC as described above. Additionally, we categorized men 
into quartiles of ALT (n = 244) and GGT (n = 241) to explore association 
between different liver enzymes, semen parameters and sex hormones in more 
detail. We calculated percentiles for GGT [(25th) 15 U/L, (50th) 21 U/L, (75th) 
35.5 U/L] and ALT [(25th) 17 U/L, (50th) 23 U/L, (75th) 37 U/L]. 
Men were also divided into three groups according to their weekly alcohol 
consumption as described in 6.2.2. Besides, 3 groups were formed based on 
alcohol consumption with or without elevated levels of liver enzymes: (I) non-
drinkers, (II) drinkers without elevated levels of liver tests, (III) drinkers with 
elevated levels of liver tests (ALT and/or GGT). When GGT levels were > 60 
U/L and ALT levels were > 41 U/L we considered them as abnormal (by United 
Laboratories of Tartu University Hospital). 
Subsequently we excluded men with only increased ALT levels (n= 7 in the 
non-drinkers group, n=31 in the drinkers with elevated levels of liver tests 
group). We compared non-drinkers with elevated ALT with normal levels of 
ALT, using t-test. We did not find any significant differences comparing data 
concerning age, reproductive hormones and semen parameters. We repeated 
analysis, but this time excluding all participants with elevated GGT levels. 
Looking at the relationship between reproductive parameters and liver tests 
we controlled for study age, BMI and alcohol consumption. Looking at the 
relationship between reproductive parameters, alcohol consumption and liver 
tests we controlled for study age and BMI. 
 
 
6.1.2. Male partners of infertile couples. 
A cross-sectional, multicentre study was conducted during the period 2008 – 
2013 at the Andrology Centres of Tartu University Hospital in Tartu and in Tal-
linn. Male partners of couples (MPIC) failing to conceive a child over a period 
of ≥12 months, irrespective of their semen analysis results were invited to 
participate. In addition to the semen analysis, the study subjects went through a 
structured medical interview and were subjected to physical examinations and 
blood tests for hormonal analysis. They also had a choice to complete a 
questionnaire in addition to performed tests. A total of the 6286 males were 
screened. 2672 men of them (42.5 %), aged 19 to 50, met the eligibility criteria. 
The flow chart (Figure 2) shows the number of subjects recruited and finally 
included in the studies. Inclusion and exclusion criteria for participants have 




6.1.2.1. The study investigating the relationships between total 
testicular volume, adiposity measures and reproductive parameters 
In order to get a clearer picture of reproductive, anthropometrical and lifestyle 
findings of men with different total testicular volumes (TTV), participants were 
divided into 6 groups according to their TTV: (I) < 37 ml, (II) ≥37 < 43 ml, (III) 
≥43 ≤ 46 ml, (IV) >46 ≤ 49 ml, (V) >49 < 51 ml, (VI) ≥51 ml. In addition, ROC 
curve analysis has been performed to determine optimal TTV cutoff value 
where men would have had normal semen analysis according to WHO refe-
rences. On the basis of the analysis the obtained cutoff value also corresponds 
to the mean TTV of the study group: (I) ≤ 46 ml; (II) > 46 ml. Thereafter, we 
calculated percentiles for BMI [(25th) 23.6 kg/m2, (50th) 26.1 kg/m2, (75th) 
29.1 kg/m2], WC [(25th) 85.5 cm, (50th) 93.0 cm, (75th) 102.0 cm] and WHtR 
[(25th) 0.472, (50th) 0.514, (75th) 0.561]. We categorized men into quartiles to 
explore associations between different surrogate measures of adiposity, semen 
parameters and sex hormones in TTV groups. Potential confounding factors 
were taken into account. In the semen analysis we included age, sexual absti-
nence time, alcohol consumption, disorders affecting testicular function, and 
TTV. In the analysis of blood samples, we controlled for age, disorders af-
fecting testicular function, alcohol consumption and TTV. 
 
 
6.1.2.2. The study of reproductive parameters in relation to 
metabolic syndrome in a group of fertile men and male partners of 
infertile couples 
In a total of 238 FM and 2642 MPIC were included in the study (Table 1, Paper 
4). To explore the association between MS, semen quality and reproductive 
hormones, four groups of men were compared: FM-MS-, FM-MS+, MPIC-MS-, 
MPIC-MS+. To investigate the association between MS and reproductive para-
meters within BMI categories, these study participants were stratified into three 
standard BMI groups: (I) <25 kg/m2, (II) 25-29.9 kg/m2, (III) ≥30 kg/m2. The 
analysis was repeated. 
MS was defined according to the 2004 updated National Cholesterol Edu-
cation Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment 
of High Blood Cholesterol in Adults (Adult Treatment Panel III) (ATP III) cri-
teria (at least three of the following criteria): waist circumference ≥ 102 cm; tri-
glycerides ≥1.7 mmol/L (150 mg/dL) or drug treatment for elevated triglycerides; 
HDL less than 1.03 mmol/L (40 mg/dL); blood pressure ≥130/85 mm/Hg or use of 
medication for hypertension; fasting glucose ≥ 5.6 mmol/L (100 mg/dL) or use of 
medication for hyperglycemia (Grundy SM et al., 2005). When determining the 
differences in semen and reproductive hormones according to MS, we adjusted 





6.2.1. Physical examination 
Testicular volumes were measured using the orchidometer (made of birch 
wood, Pharmacia & Upjohn, Denmark) and expressed in milliliters. The total 
testes volume was the sum of right and left testicles. The position of the testicles 
in the scrotum and disorders affecting testicular function [i.e. varicocele (gr 2, 3 
and bilateral), testicular trauma, inguinal hernia] were recorded. Examination of 
patients has been described in detail elsewhere (Punab et al., 2017). A face-to-
face clinical interview was conducted to assess the presence of other medical 
conditions and lifestyle related risk factors. All research personnel underwent 
the NHANES “Anthropometry Procedures Manual” based training programme 
(NHANES, 2007). Height was measured by roll-up metal length measuring tape 
for wall mounting rounded to the nearest 0.1cm and expressed in cm respec-
tively. Body composition was determined using Tanita Body Composition Ana-
lyzer (TBF-300MA). Beside weight in kg, actual fat mass in kg and BF% were 
defined by body analyser. Recommended by Tanita, a standardized BIA pro-
tocol was used in order to obtain the most accurate results (Heyward V et al., 
1996). BMI was defined as the weight in kilograms divided by the square of the 
height in meters (kg/m2). The WC was measured halfway between the iliac crest 
and the bottom of the 12th costal bone, at the end of normal expiration and 
expressed in cm. The nurse took two measurements rounded to the nearest 
0.1cm and a third if the difference was more than 1 cm. WHtR was defined as 
waist circumference divided by height, both measured in the same units. The 
measurement of blood pressure was performed by using the Omron M3W, an 
electronic digital device for measuring blood pressure in the arm while the 




In addition, all men (FM and MPIC) were asked to complete a questionnaire to 
provide information on medical and reproductive history and lifestyle factors 
including alcohol and smoking history.  
To screen for drinking habits the AUDIT self-reported questionnaire was 
used (Babor TF et.al, 2001). Men were asked to convert their intake to alcohol 
units. One unit of alcohol was defined as 10 grams of pure alcohol. Alcohol 
intake was calculated as the sum of daily reported unit intakes within that week. 
In addition, the men were asked whether their alcohol intake in the week 
represented habitual alcohol consumption. They were also asked how often they 
drink, how many units they consume on one occasion and how many times they 
consume more than 6 units of alcohol. As Estonia does not have nationally 
determined explicit limits for weekly alcohol consumption, the daily limits and 
alcohol-free days were used to derive the cut-off points for this analysis 
(www.alkoinfo.ee). Men were divided into 3 groups according to their drinking 
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habits: (I) non-drinkers, (II) moderate drinkers (< 16 units/week), (III) habitual 
drinkers (≥ 16 units/week). 
Men were also divided into 3 groups according to smoking status: (I) non-
smokers, (II) former-smokers, (III) smokers. 
Medical history included questions about obesity and infertility related 
chronic diseases such as various endocrinopathies, asthma, neurological dis-




6.2.3. Semen analysis 
Semen quality parameters like semen volume, concentration, total sperm count, 
motility and morphology were assessed. The analysis of semen samples was 
performed in accordance to WHO recommendations at the time of recruitment 
(WHO, 1999; WHO, 2010). Semen samples were obtained by masturbation 
after a required abstinence period of minimum 2 days and ejaculated into a 
sterile collection tube in a private room near the laboratory. Artificial lubrica-
tion was not allowed for semen collection. After ejaculation, the semen was 
incubated at 37°C for 30–40 min for liquefaction. The actual period of ejacula-
tion abstinence was calculated in days between current and previous ejaculation 
as reported by the men. Semen volume was estimated by weighing the collec-
tion tube with the semen sample and subsequently subtracting the pre-
determined weight of the empty tube assuming 1 g = 1 ml. For assessment of 
the sperm concentration, the samples were diluted in a solution of 0.6 mol/l 
NaHCO3 and 0.4% (v/v) formaldehyde in distilled water. The sperm concentra-
tion was assessed using the improved Neubauer haemocytometers. Total sperm 
count was calculated by multiplying semen volume by sperm concentration. 
The motility assessment was performed in duplicate and the average value was 
calculated. Motility was assessed in order to report the number of progressively 
motile spermatozoa (WHO motility classes A + B). Smears for morphology 
assessment were made. Following fixation and Papanicoulaou staining morpho-
logy was assessed according to strict criteria (Menkveld et al., 1990). Semen 
smears were used for detecting white blood cells. The smears were air-dried, 
Bryan-Leishman stained, and examined with the use of oil immersion micro-
scopy (magnification: ×1000). Polymorphonuclear leukocytes were diffe-
rentiated from spermatids by the presence of segmented nuclei, bridges between 
lobes of nucleus, and specific granulation of the cytoplasm. The leukocyto-
spermia was defined according to WHO definition for the neutrophil count > 
1million/ml.  
The sperm analyses were performed at the Andrology Centres of Tartu 
University Hospital in Tartu and in Tallinn. Special emphasis was paid to the 
quality assurance and control procedures with follow WHO guideline (WHO, 
2010). The laboratory technicians performing semen analysis in both centres 
had similar training background and have been participated in several semen 
analysis standardisation workshops and external quality control schemes 
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organized in the framework of Nordic-Baltic scientific collaboration. Our tech-
nicians performed regular intralaboratory control by examining the same semen 
samples blindly and the between-technician variation in sperm concentration 
was constantly <10%. 
 
6.2.4. Blood sampling 
Blood samples were taken between 8 am and 10.30 am after an overnight fast 
same day that the semen sample was produced. Blood was centrifuged and 
serum was used to determine of testosterone, oestradiol (E2), follicle-stimu-
lating hormone (FSH), luteinizing hormone (LH), sex hormone binding globulin 
(SHBG) and insulin concentrations concentrations by chemiluminescence 
immunoassay (CLIA) method (Immulite 2000, Siemens Healthcare Diagnostics, 
Deerfield, IL, USA). 
Hexokinase method was used for serum glucose, enzymatic colorimetric 
method was used for HDL cholesterol, triglycerides and GGT assays (Cobas c 
501, Roche, Basel, Switzerland) and for ALT a kinetic photometric method 
were used (Cobas 6000; Roche Diagnostics CH – 6343 Rotkreuz, Switzerland). 
 
 
6.2.5. Statistical analysis 
The assumption of normality was checked for parametric tests. The histogram 
and the P-P (probability-probability) plot were used to test for normality. The 
data regarding semen volume, sperm concentration and total sperm count were 
positively skewed. Skewed data were normalized by the natural log-trans-
formation before analysis. The back-transformed adjusted mean values ensured 
the most reliable results and were used for evaluation. 
Spearman´s correlation coefficient was calculated between BMI, BF%, WC 
and WHtR.  
The independent t-test or the analysis of variance (one-way ANOVA model 
with Bonferroni’s multiple t-tests by pairwise group comparison) was applied to 
test for significant differences between the formed groups and the various para-
meters (reproductive, anthropometric, lifestyle parameters), with P < 0.05 
considered statistically significant.  
Pearson chi-square test was used to investigate whether distributions of 
categorical variables differ from one another.  
To reduce the error variance and give a clearer picture of the outcome we 
also took known potential confounding factors into account using analyses of 
covariance (ANCOVA) with Bonferroni-corrected post-hoc pairwise com-
parisons. 
Missing information on smoking status and alcohol consumption restricted 
our data set. We compared two groups of men (with whole data and with mis-
sing values) using t-test. We did not find any significant differences comparing 
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data concerning age, testicular volumes, reproductive hormones and semen 
parameters. 
The results are presented as mean (95% confidence intervals [CIs]), median 
with the 25th and 75th percentiles and as adjusted back-transformed mean 
values (95% CIs). Data analyses were performed using the SPSS for Windows 
version 20.0 (SPSS Inc. Chicago, IL). Statistical significance was defined as p < 
0.05 
 
 6.2.6. Ethical considerations 
Participation in the study was voluntary. Studies were approved by the Ethics 
Committee on Human Research of the University of Tartu and written informed 
consent was obtained from all participants. (certificate 152/4, 2006 and certi-




7. RESULTS AND DISCUSSION 
7.1. Prevalence and characteristics related to adiposity and 
metabolic syndrome among the Estonian fertile men and 
male partners of infertile couples 
7.1.1. Prevalence and characteristics related to adiposity  
(Papers 1, 2, 3, 4) 
Men in the MPIC group had a significantly higher mean BMI compared to FM. 
Central obesity defined by high risk WC (≥ 102 cm) and WHtR (> 0.5) was also 
more prevalent among these men. Clinical findings are shown in Table 2. In 
2016, 59.9% of men in the general population were overweight or obese 
(Tekkel M, 2017). Compared to the general population less overweight and 
obese men was found in the FM group (51.2%). The prevalence of overweight 
and obesity was almost comparable between men in the general population and 
MPIC (60.4%). 
According to BMI categories men with overweight and obesity, in both 
groups (FM and MPIC), were older (p=0.009; p<0.001, respectively) and the 
percentage of overweight and obesity increased with age. 28 (29.8%) of FM and 
343 (35.0%) of MPIC under the age of 30 were overweight (BMI ≥25<30) 
while 9 (9.6%) of FM and 152 (15.5%) of MPIC were obese (BMI ≥ 30). At the 
same time, over the age of 40, 10 (32.3%) of FM and 144 (46.9%) of MPIC 
were overweight while 9 (29.0%) of FM and 83 (27.0%) of MPIC were obese. 
Likewise, the age-related rise in overweight and obesity among men in the 
general population can be noticed. In 2016, 10.7 % of 25- to 34-year-olds and 
27.2 % of 45 to 54-year-olds were obese (Tekkel M, 2017). 
From men who self-reported their 5 years earlier weight, 107 (55.2%) of FM 
and 631 (58.3%) of MPIC gained and 48 (24.7%) of FM and 259 (23.9%) of 
MPIC maintained weight during the period. 
The higher prevalence of adiposity among MPIC has been accompanied by 
increased levels of liver enzymes (GGT, ALT) compared to FM. However, 
highly significant positive relationship was also obtained between liver tests and 
every BMI as well as WC group in FM (Paper 2, p<0.001 for both parameters). 
Likewise, earlier studies have found that BMI, WC and visceral fat mass are 
positively associated with ALT and GGT levels (Adams et al., 2008; Verrijken 









Table 2. General characteristics of study groups. 
 FM MPIC P 
(n =260) (n =2672) 
Personal characteristics, mean ± SD
Age in year 32.3 (± 6.7) 32.6 (±5.7) .475 
Height (cm) 180.5 (± 6.1) 181.3 (±6.9) .065 
BMI   (kg/m2) 25.7  (±3.8) 26.6 (±4.5)   .009 χ2 
<25 n (%) 127 (48.8%) 1056 (39.6%)  
≥25<30 n (%) 95 (36.5%) 1083 (40.5%)  
≥30 n (%) 38 (14.7%) 533 (19.9%)  
BMI 5 years ago a (kg/m2) 24.7 ( ±3.6) 25.1 ( ±3.9)    .142 
Waist circumference (cm) 91.0 ( ±9.7) 94.3 ( ±12.4)  <.001 χ2 
<94 n (%) 165 (63.5%) 1343 (50.3%)  
≥94<102 n (%) 57 (21.9 %) 631 (23.6 %)  
≥102 n (%) 38 (14.6 %) 698 (26.1%)  
Waist-to-height ratio 0.504 (± 0.055) 0.521(±0.067) .002 χ2 
≤0.5 n (%) 136 (52.3%) 1128 (42.2%)  
>0.5 n (%) 124 (47.7%) 1544 (57.8%)  
Health and lifestyle characteristics, n (%)
Metabolic syndrome b 29 (12.2%) 471 (17.8%)   .028 χ2 
ALAT U/L 30.1 (21.1%) 33.4 (24.2%) .043 
GGT U/L 28.9 (21.0%) 34.6 (40.6%) .035 
Smoking status c   <.001 χ2 
Never smoker 105 (41.8%) 435 (22.1%)  
Former smoker 74 (29.5%) 622 (31.6%)  
Current smoker 72 (28.7%) 914 (46.4%)  
Alcohol statusd     .036 χ2 
Non alkohol users  45 (18.0%) 230 (12.2%)  
< 16 units/week 162 (64.8%) 1318 (70.0%)  
≥ 16 units/week 43 (17.2%) 334 (17.8%)  
Units per week, mean± SD 7.7 (± 8.2) 8.7(± 11.1) .176 
a  FM: 66 missing, MPIC: 1589 missing; b FM: 22 missing, MPIC: 30 missing; c FM: 
10 missing, MPIC: 701 missing; d FM 10 missing, MPIC: 790 missing 







7.1.2. Prevalence and characteristics related to metabolic 
syndrome (Paper 4) 
To the best of our knowledge, this study was the first to report a significantly 
higher prevalence of MS in MPIC compared to FM of the same age range 
(Table 2). The observed difference was 5.6 %. Our findings showed that 17.8% 
of MPIC presenting for couples’ infertility met the criteria for MS of which the 
rate is higher than in previously reported findings (Lotti et al., 2013; Venti-
miglia et al., 2016a,b). The difference between studies may come from the used 
definition and the prevalence of MS differing across countries as shown by 
Scuteri et al., (2015). We chose the adapted NCEP-ATP III criteria to define 
MS because this definition does not require insulin resistance or central obesity 
as a necessary diagnostic component and is widely used. The prevalence of MS 
among men in the general population was higher compared with our results. MS 
was found in 25.7 % of 20- to 44-year-olds men and 28.2 % of 45 to 60-year-
olds men (Eglit et al., 2012). 
When stratifying FM and MPIC according to the presence or non-presence 
of MS men with MS, in both groups, were centrally obese as indicated by 
increased WC, WHtR and BMI (Table 3). Still, in the presence of MS 3.4% of 
the FM and 6.8% of the MPIC were categorized as normal-weight (BMI  
<25 kg/m2). Besides central obesity, other metabolic syndrome indicators (low 
HDL-cholesterol, elevated triglycerides and blood pressure levels) in both MS+ 
groups have been found (Table 3). However, glucose concentrations were 
significantly higher only in the MPIC-MS+ group. Higher levels of fasting 
glucose were more frequently found in MPIC-MS+ (51.2%) than in FM–MS+ 
(10.3 %). Furthermore, higher insulin levels were found in MPIC-MS+ (data 
available only for MPIC).  
Men with MS were older although a significant correlation was seen only in 
the MPIC group. Irrespective of the definition, the existence of a similar age-
profile has been confirmed earlier (Lotti et al., 2013; Ventimiglia et al., 2016). 
Interestingly, the most frequent metabolic components in subjects with MS 
were different between our study and study made by Eglit et al., 2012. Higher 
triglycerides (93.1% of FM and 80.1% of MPIC), arterial hypertension (78.6% 
of FM and 77.7% of MPIC) and abdominal obesity (75.9% of FM and 74.3% of 
MPIC) were the most common abnormalities in our study. At the same time, a 
population-based cross-sectional study in different counties of Estonia showed 
that arterial hypertension (94%), abdominal obesity (91%) and impaired glucose 
metabolism (71%) were the most frequent metabolic components in men with 
MS (Eglit et al., 2012). It is probable that the prevalence of metabolic variables 
is dependent on age. On average, men in our study were younger than men in 
study made by Eglit et al., 2012. 
Disorders potentially affecting testicular function and leucocytospermia were 





































   








   
   































































































































































































































































































































































































































































































































































































































































































7.2. General characteristics related to  
reproductive parameters  
Overall, 78.5% of FM and 46.9% of MPIC had totally normal semen analysis ac-
cording to WHO 2010 guidelines. Significantly lower TTV, semen quality 
(except for semen volume) and higher level of FSH, a common indicator of 
spermatogenesis impairment, were seen in MPIC compared to FM (Table 4). At 
the same time testosterone, oestradiol and LH levels did not differ between the 
two groups.  
Besides, the quartile analysis revealed that distributions of total sperm count 
and sperm concentration in both groups followed inverted J-shaped curve. Even 
if we did not find statistically significant associations, J-shaped curves appeared 
between BMI, WC, BF% quartiles and sperm parameters in FM (Figure 3 A, 
BMI and total sperm count). In MPIC same trend appeared between BMI, WC 
quartiles and mentioned sperm parameters (Figure 3 B, BMI and total sperm 
count). Similar associations were already found before between total sperm 
count (Jensen et al., 2004; Stewart et al., 2009), sperm concentration (Jensen et 





Table 4. Reproductive parameters of study groups. 
 FM MPIC P 
(n =260) (n =2672)  
Total testicular volume (ml) 
Mean (95% CI) 47.7 (46.5; 48.8) 45.9 (45.5; 46.2) <.004 
Abstinent time (day) 
Mean (95% CI) 3.9 (3.7; 4.1) 3.8 (3.7; 3.9) .245 
Semen volume (mL) 
Mean (95% CI) 3.8 (3.6; 4.0) 3.8 (3.7; 3.9) .899 
Sperm concentration (×106/mL)
Mean (95% CI) 73.3 (66.4; 81.0) 38.2 (36.3; 40.1) <.001 
Total sperm count (×106) 
Mean (95% CI) 280.3 (252.7; 311.1) 144.0 (136.5; 151.1) <.001 
Motile spermatozoa (%) 
Mean (95% CI) 51.5 (50.0; 52.9) 41.4(40.7; 42.0) <.001 
Normal morphology (%) 
Mean (95% CI) 10.7 (10.1; 11.4) 7.0 (6.8; 7.2) <.001 
Serum FSH (IU/L) 
Mean (95% CI) 3.9 (3.7; 4.2) 4.4 (4.3; 4.5) .027 
Serum LH (IU/L) 
Mean (95% CI) 3.7 (3.5; 4.0) 3.7 (3.6; 3.8) .951 
Testosterone (nmol/L) 
Mean (95% CI) 16.7(15.9; 17.4) 16.6 (16.4; 16.9) .959 
Oestradiol (pmol/L) 
Mean (95% CI) 124.7 (118.5; 130.9) 127.4 (125.3; 129.6) .427 
Health characteristics, n (%)
Testicular disorders a 43 (16.5) 506 (18.9) .405 χ2 
a Testicular  disorders: varicocele (gr 2, 3 and bilateral), testicular trauma, inguinal 










J-shaped curve between BM
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I and total sperm count in FM (A) and in
 
 
 MPIC (B).  
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7.3. Obesity and metabolic syndrome related changes in 
male reproductive health 
7.3.1 The different surrogate measures of adiposity in  
relation to reproductive parameters among  
Estonian Fertile Men (Paper 1) 
After adjustment for covariates a high BF%, WC and WHtR were negatively 
associated with total sperm count (Table 3, 4, 5 in Paper 1). A post hoc test 
showed that men in the fourth quarter (BF% ≥ 23.4; WC > 98 cm) had a 
significantly lower total sperm count [217.2 (95% CI: 177.0; 266.7); 208.9 
(95% CI: 170.2; 256.7), respectively] compared with men in the second quarter 
(BF% ≥ 15.7 < 19.6; WC ≥ 84 ≤ 90 cm) [322.5 (95% CI: 263.0; 395.1) (p = 
0.049); 329.3 (95% CI: 268.8; 403.4) (p = 0.014), respectively]. Similar trend 
also appeared between the fourth and the third quarter (BF% ≥ 19.6 < 23.4; WC 
> 90 ≤ 98 cm) [317.7 (95% CI: 260.1; 388.0) (p = 0.05); 305.2 (95% CI: 249.9; 
372.4) (p = 0.056), respectively]. The generally accepted cut-off value for the 
study of adverse effects of WC is 102 cm. It was also confirmed by Hammiche 
et al. (2012). Based on our analysis; the sensible cut-off value might be smaller, 
as we show that the effects of WC on total sperm count are seen from a WC > 
98 cm. Looking at WHtR, men in the fourth quarter (WHtR ≥ 0.540) had a 
lower total sperm count [219.0 (95% CI: 178.6; 268.5)] compared this time with 
men in the first quarter (WHtR < 0.463) [338.0 (95% CI: 274.8; 415.7) (p = 
0.024)]. Moreover, the BF% was also negatively correlated with semen volume. 
A post hoc test showed that significant difference appeared between men in the 
fourth [3.5 (95% CI: 3.1; 3.9)] and the second quarter [4.4 (95% CI: 3.9; 4.8)  
(p = 0.034)].  
In addition to the results of our study, other researchers have reported that 
WC is inversely correlated to semen volume (Fejes et al., 2005, Hammiche et 
al., 2012; Eisenberg et al., 2014), sperm motility (Fejes et al., 2005, Hammiche 
et al., 2012) and sperm concentration (Hammiche et al., 2012).  
Next to these changes the BMI was not related to sperm parameters. This is 
in contrast to studies and recent review with meta-analysis that have shown an 
association between BMI and sperm parameters (Chavarro et al., 2010; Shayeb 
et al., 2011; Hammiche et al., 2012; Eisenberg et al., 2014; Andersen et al., 
2015; Guo et al., 2017).  
As demonstrated previously (7.2), distributions of total sperm count and 
sperm concentration followed inverted J-shaped curve. However, we did not 
find statistically significant associations between low weight and sperm para-
meters as did Jensen et al. (2004), but there were not also really underweight 
men in our study group. At the same time, the curves obtained may explain why 
we did not find significant differences in sperm count (regarding BF% and WC) 
between men in the fourth and in the first quarter. 
As regards the hormone parameters, in line with other studies, all adiposity 
markers were negatively related to SHBG and total testosterone levels (p<0.001 
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for all). Low testosterone levels linked to obesity is confirmed by different re-
searches (Jensen et al., 2004; Fejes et al. 2005; Aggerholm et al., 2008; Wu et 
al., 2008; Chavarro et al., 2010; Rohrmann et al., 2011; Macdonald, et al., 2013; 
Lu JC, 2015). The main reason for this decline is thought to be the decrease of 
SHBG production (Rohrmann et al., 2011; Fejes et al., 2005). Rohrmann et al. 
(2011) offered that SHBG is probably more strongly affected by abdominal than 
overall obesity. Levels of fasting glucose and excess monosaccharide con-
sumption rather than elevated insulin levels are potential explanations for 
declining SHBG (Selva et al., 2007; Peter et al., 2010). 
Concomitantly, testosterone levels in obesity can decline due to increased 
peripheral conversion of androgen to oestrogen which is attributed to higher 
oestradiol levels and suppression of the HPG axis (Schneider et al., 1979; Kley 
et al., 1980). However, only some articles show positive associations between 
adiposity markers and oestradiol levels (Rohrmann et al., 2011; Chavarro et al., 
2010; Jensen et al., 2004). In our study, WHtR as well as BMI, BF% and WC 
were not related to oestradiol. 
Majority of the studies, among them ours, have not found correlation 
between adiposity and gonadotropin levels (Jensen et al., 2004; Fejes et al., 
2005; Aggerholm et al., 2008; Chavarro et al., 2010; Lu et al., 2015).  
To our knowledge, these study findings were the first to show a relationship 
between sperm parameters and two adiposity markers (BF% and WHtR) and 




7.3.2. The relationships between total testicular volume, 
reproductive parameters and surrogate measures of adiposity 
(Paper 3) 
7.3.2.1. Total testicular volume, body composition and  
male reproductive healt parameters 
The mean and the median of the MPIC study group TTV was 46 ml, which con-
firms the results of earlier studies (Jørgensen et al., 2002; Erenpreiss et al., 
2017). 
Parameters characterising height and body composition had a strong 
relationship with TTV. There is a certain logic to the assumption that taller men 
have a larger TTV, which has been approved in different studies (Handelsman 
et al., 1985; Ku et al., 2002; Hart et al., 2015), including ours. In addition, a 
positive correlation between BMI, WC, WHtR and the TTV was found 
(p<0.001 for all) (Table 2 in Paper 3).  
Regarding reproductive parameters, positive correlations between the TTV 
and total sperm count, sperm concentration, -morphology, -motility (p<0.001) 
and semen volume (p=0.005) were found. The men with the largest TTV (TTV 
≥ 51 ml) had a mean total sperm count of over four times higher [254.2 × 
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106/ml (95% CI: 231.5; 279.2)] than the men with the lowest TTV [TTV  
<37 ml: 56.0 × 106/ml (95% CI: 47.8; 65.5)]. Other researchers have shown 
similar effects (Sakamoto et al, 2008a; Bahk et al., 2010; Tijani et al, 2014; 
Ventimiglia et al., 2017). The gonadotropins were negatively (p <0.001) and the 
testosterone was not correlated to the TTV which have been confirmed earlier 
(Bujan et al., 1989; Hart et al., 2015). On the other hand, some studies have 
found a positive correlation between testosterone and the TTV (Sakamoto et al., 
2008a; Bahk et al., 2010). In men with a smaller TTV, a comparable testo-
sterone level to those with a larger TTV was achieved, apparently due to an in-
crease in LH levels. As outlined previously, the small testes’ Leydig cell 
function might be better preserved than the seminiferous tubule function (Saka-
moto et al., 2008b). 
There were no significant differences between the TTV groups when com-
pared for chronic diseases. At the same time, disorders potentially affecting 
testicular function, especially varicocele, were more prevalent among men with 
lower testicular volume (p<0.001). The relationship between varicocele and 
smaller testis volume have shown by Hart et al. (2015). Men with higher testi-
cular volume were older and they consumed significantly more alcohol 
(p=0.006, p=0.023, respectevly). Rastrelli et al., 2013 have also demonstrated a 




7.3.2.2. The relationships between surrogate measures of adiposity 
and reproductive parameters in different TTV groups (Paper 3) 
Clear differences in semen quality between BMI, WC, WHtR and the TTV 
groups were seen. Importantly, men with the smaller testicles (TTV ≤ 46 ml) 
were more affected. In the case of a TTV ≤ 46 ml, all three measures (BMI, 
WC, WHtR) were negatively associated with the total sperm count (p=0.003, 
p=0.008, p=0.001) and the sperm concentration (p=0.005, p=0.015, p=0.002). 
Significant differences were found between the first and the fourth quarter. 
These changes appeared from a BMI ≥ 29.1, WC ≥ 102 cm and WHtR ≥ 0.56. 
Decline in semen quality was more pronounced between WHtR and the TTV 
(Table 3 in Paper 3). As mentioned above, lower sperm count and -con-
centration [84.5 (95% CI: 71.2; 100.4), 24.3 (95% CI: 20.6; 28.8), respectively] 
in the fourth quarter were found compared with men in the first quarter [130.2 
(95% CI: 115.2; 147.1), 33.1 (95% CI: 29.4; 37.2), (p=0.01, p=0.01), respec-
tively]. 
In the case of a TTV > 46 ml, BMI, WC and WHtR were inversely cor-
related only with the semen volume (p=0.085, p=0.03, p=0.01).  
As in the previous study (7.3.1), adiposity parameters were not related to the 
LH and FSH levels but they were related to the total testosterone levels in both 
TTV group (for all parameters p <0.001). At the same time, no statistically 
significant differences were observed when comparing testosterone levels 
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within the WHtR, WC and BMI quartiles in the TTV groups. With respect to 
adjusted means of oestradiol, a certain positive association with anthropometric 
parameters can be seen in the group of TTV > 46 ml, but the post hoc test did 
not confirm these significant relationships between the groups (excluded form 
paper). 
To our knowledge, the findings of this study are the first to show that in the 




7.3.3. The relationships between metabolic syndrome and 
reproductive parameters (Paper 4) 
Even if the prevalence of MS has been suggested as a possible risk factor that 
can attribute to infertility, the evidence linking MS with impaired semen para-
meters is still conflicting. When stratifying men into four groups, MS had no 
independent effect on major fertility parameters in different subgroups of men 
(Table 3 in Paper 4). Likewise, no significant differences were found between 
MS and semen parameters within the BMI categories (Table S1 in Paper 4). 
Significant differences in semen quality were only obtained between FM and 
MPIC groups. Conversely, some other studies have found decreased semen 
quality in men with MS (Lotti et al., 2013; Leisegang et al., 2014; Ventimiglia 
et al., 2016a; Elsamanoudy et al., 2016). Nevertheless, negative correlation 
between semen parameters and MS from mentioned studies was obtained from 
MPIC, infertile men and men from a specific region of South Africa who were 
older compared to our study groups. 
Regarding reproductive hormones, testosterone was strongly correlated to 
MS (p < 0.001) (Table 3 in Paper 4). This negative association persisted even 
after an adjustment for covariates within the BMI categories, but only between 
MPIC-MS- and MPIC-MS+ groups (post hoc test p < 0.001 for BMI 25–29.9). A 
negative association between testosterone levels and MS have been confirmed 
by many researches (Laaksonen et al., 2003; Corona et al., 2006; Lotti et al., 
2013; Ventimiglia et al., 2016a,b) and a systematic review with meta-analysis 
showed that MS is significantly and independently associated with an overall 
lower total testosterone levels (Corona et al., 2011). 
In MPIC, LH was negatively correlated to MS (p=0.048) (Table 3 in Paper 
4). In spite of statistically negative results, the same trend was seen within BMI 
groups. As already demonstrated before lower LH levels could be explained by 
larger testicles (Sakamoto et al., 2008a) and MS was positively correlated to the 
TTV seen in MPIC (p<0.001) (Table 2 in Paper 4). FSH as well as oestradiol 





7.3.4. The relationships between liver tests and reproductive 
parameters (Paper 2) 
Performed analysis showed that GGT was negatively related to sperm con-
centration and total sperm count (Table 5) (Table 2 in Paper 2). These signi-
ficant changes appeared from a GGT >35.5 U/L. A post hoc test demonstrated 
that men in the 4th quarter had a significantly lower sperm concentration and 
total sperm count compared with men in the other quarters. The present results 
revealed, for the first time, an association between semen quality and GGT. 
Next to these changes ALT was not related to sperm parameters.  
Both enzymes, GGT and ALT, were not related to reproductive hormoone 
levels. 
The data on associations of liver enzymes and male reproductive health is 
limited. Only one previous research has been shown that NAFLD non-obese 
men had significantly poorer sperm quality and lower testosterone and LH 
levels compared with healthy men without fatty liver (Li Y et al., 2015).  
 
 
Table 5. Distribution of sperm count and -concentration according to GGT. 
 GGT(n=241)
   25th = 15 U/L          50th 21 U/L            75th = 35.5 U/L P 
value (n = 61) (n = 60) (n = 60) (n = 60) 










(43.1; 67.7) .015 










(161.9; 260.5) .033 
Sperm parameters were adjusted for BMI, age and alcohol use. ANCOVA with 
Bonferroni-corrected post-hoc pairwise comparisons was used. 
 
 
7.4. Pattern of alcohol use and the relationship between 
alcohol consumption, body composition, liver tests and 
reproductive parameters  
7.4.1. Pattern of alcohol use and the relationship between 
alcohol intake and body composition 
Even if the analysis’ results proved no significant difference in the mean 
amount of alcohol consumed, FM drank less (7.7 units per week) than MPIC 
(8.7 units per week) (Table 2). At the same time, the alcohol status differed 
significantly between those groups. Compared to MPIC, more non-drinkers and 
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less moderate drinkers (< 16 units/week) were found among FM. According to 
the NIHD, drinking more than 16 units (alcohol) per week for men is defined as 
heavy drinking (NIHD, 2010). Almost a fifth of our study subjects (FM and 
MPIC) consumed alcohol ≥16 units per week (Table 2). The prevalence of 
heavy drinking was slightly higher (21%) among men in the general population 
(Tekkel M, 2017). 
After studying the relationship between alcohol intake and body composition 
in FM (Paper 2), analysis was repeated in MPIC. The results are shown in Table 
6. After correction for age, alcohol consumption was positively correlated to 
BMI, WC and WHtR in both groups. Based on available data, increased energy 
intake with alcohol use can promote a positive energy balance and weight gain 
(Lukasiewicz et al., 2005; Niemelä et al., 2017; Alatalo et al., 2008; Downer et 
al., 2017).  
Moreover, we showed that in both groups (FM and MPIC) there were more 
overweight and obese men than normal-weight men who consumed ≥ 16 units 
per week (p=0.035, p=0.029, respectively). 
 
 
Table 6. The association between alcohol intake and body composition. 












n=334 FM MPIC 
BMI (kg/m2) 












(4.4) 0.01 0.016 
WC (cm) 












(12.4) 0.022 <0.001 
WHtR 












(0.67) 0.013 0.001 
FM 10 missing, MPIC 790 missing. The independent t-test was used.  
 
 
7.4.2. Alcohol consumption in relation to liver tests and 
reproductive parameters (Paper 2) 
A positive correlation between liver tests and drinking was found, but after 
adjustment for covariates only GGT levels stayed significantly related to 
alcohol consumption. Positive correlation revealed between non-drinkers [24.2 
(95% CI:18.7; 29.7)] and habitual drinkers [36.0 (95% CI: 30.3; 41.6) (p = 
0.012)] and also between moderate drinkers (28.0 (95% CI: 25.2; 30.8) and 
habitual drinkers groups (p= 0.043). It has been previously confirmed that 
serum GGT activities in drinkers were higher than that in abstainers (Alatalo et 
al., 2008; Tynjälä et al., 2012).  
Forming three groups based on men’s weekly alcohol consumption, we did 
not find any relationship between drinking and semen quality, which is con-
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sistent with previous international cross-sectional study (Jensen et al., 2014). 
Thereafter, analysis based on alcohol consumption with or without elevated 
levels of liver enzymes was made. A post-hoc test showed that after adjustment 
for covariates men who consumed alcohol and had also increased liver enzymes 
(ALT > 41 U/L and/or GGT > 60 IU) had significantly lower sperm con-
centration compared with men without elevated liver enzymes but who 
consumed alcohol (p=0.038). Having found that ALT levels were not related to 
sperm parameters (7.3.4.) and alcohol consumption, we excluded men with only 
increased ALT for the next analysis. In our study, elevated GGT levels  
(> 60 IU) (n=17) were found only among alcohol users irrespective of the 
amount of alcohol consumed. A post-hoc test revealed that drinkers with 
elevated GGT had twisely lower total sperm count compared with drinkers 
without elevated GGT (p=0.010) and with non-drinkers (p=0.029) (Table 7) 
(Table 3 in Paper 2). Likewise, drinkers with elevated GGT had a significantly 
lower sperm concentration compared with drinkers without elevated GGT 
(p=0.009). To the best of our knowledge, this is the first report describing a 
probable connection between increased GGT, alcohol consumption, and semen 
quality. 
Abnormal liver tests, related to alcohol consumption, were not associated to 
reproductive hormones. When we repeated analysis but excluded all partici-
pants with elevated GGT levels we did not find any relationship between 








No ALCO ALCO+ ALCO+/GGT P value 
(n = 35) (n = 146) (n = 17)  
Sperm concentration (×106 per mL)







Total sperm count (× 106) 








ALCO+: drinkers without elevated GGT; ALCO+/GGT: drinkers with elevated GGT. 
Sperm parameters were adjusted for age and BMI. ANCOVA with Bonferroni-corrected 







8. GENERAL DISCUSSION 
The general aim of this work was to investigate the role of adiposity in male 
infertility to increase knowledge of the reproductive consequences of obesity 
and obesity-related health and lifestyle conditions. 
 
8.1. Differences in semen quality between  
FM and MPIC groups  
Significantly lower semen quality (except for semen volume) was seen in MPIC 
compared to FM. Even if we excluded all cases with aspermia, azoospermia, 
absolute and severe causal factors of infertility forming MPIC study group, 
twisely lower mean sperm count and -concentration have been found compared 
to FM. We may hypothesize that one reason for such differences in semen 
quality can be related to differences in adiposity parameters. We showed that 
there were almost 10 % more overweight and obese men, 11.5 % more men 
with WC ≥ 102 cm and 10.1 % more men with WHtR > 0.5 in the MPIC group 
compared to FM. Leukocytospermia and testicular disorders may also be 
associated with poor sperm quality. However, we did not find any significant 
differences between the results of FM and MPIC.  
 
 
8.2. The relationships between body composition,  
TTV and semen quality 
One of the main findings of the research indicated clearly that body composi-
tion plays an important role in male infertility. In both groups (FM and MPIC), 
central obesity was negatively related to semen quality. In FM, BF% ≥ 23.4 %, 
WC > 98 cm and WHtR > 0.54 were all negatively associated with lower total 
sperm count whereas we failed to show associations between BMI and sperm 
parameters. With further research conducted in MPIC, we found that adiposity 
was continually associated with reduced semen quality, but the obtained results 
differed in different subgroups of men. Looking at the anthropometric para-
meters, it would be logical to expect that WHtR remains unchanged when the 
TTV increases, but TTV-associated parallel increase of WHtR and WC can be 
seen. The latter indicates a problematic accumulation of fat in the waist region, 
seen more in men with a larger TTV. In spite of the results, sperm parameters of 
centrally obese MPIC (BMI ≥ 29.1; WC ≥ 102 cm; WHtR ≥ 0.56) with a TTV 
of ≤ 46 ml seem to be affected more by weight increase, whereas being over-
weight may not play such a significant role in men with a TTV > 46 ml. Most of 
the volume of the testis is made up of seminiferous tubules and as shown by the 
results, men with larger testicles were able to produce more sperm than men 
with a smaller TTV. Therefore, men with smaller testicles, even when 
considered in good health, are more at risk. It is probable that abnormal sperm 
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quality is reached more quickly by damage related to lifestyle, environmental 
factors or health problems. On the other hand, fertility problems caused by 
obesity have probably delayed onset in men with a larger TTV because of better 
reproductive potential. A positive correlation between testicular volume and 
weight has already been shown (Handelsman et al., 1982; Spyropoulos et al., 
2002; Bahk et al., 2010) while, to our knowledge, there have been no obesity-
related infertility studies done in different TTV groups.  
Any persisting changes in our health status require time. Together with the 
TTV, the duration and/or the severity of the adiposity presumably determines, at 
least partially, a decline in fertility parameters. Even if more than half of the 
men surveyed (FM and MPIC) had gained the weight during 5 years, normal 
sperm analyses were still obtained from more than three-quarters of FM and 
almost half of MPIC. Taking into account the relatively low average age of our 
subjects, this might be one of the factors that help to explain the obtained results 
in relation to sperm quality. 
In addition to obesity, low weight may reduce sperm quality. Despite the fact 
that we did not find significant associations between low weight and sperm 
parameters we showed that distributions of total sperm count and sperm 
concentration followed inverted J-shaped curve. 
 
 
8.3. Comparison of different surrogate  
measures of adiposity  
Although there is no perfect marker to describe exact body composition, our 
results confirmed that, beside BMI, there could be more informative measures 
of central obesity and adiposity as indicators of male reproductive health. We 
showed that semen quality was most strongly correlated with WC and BF% in 
FM. In addition, WHtR seemed to be more predictive surrogate measure of 
adiposity in the association between TTV and male infertility in MPIC. 
While estimating the effect of obesity on male reproductive parameters, BMI 
is the most commonly used indicator but BMI alone gives no information on the 
location of body fat (Chan et al., 2003). Taking into account that men are 
genetically predisposed to develop intra-abdominal obesity, BF%, WC or 
WHtR might be better markers to determine the influence of adiposity on male 
reproductive function. Unfortunately, evidence-based cut-off points for BF%, 
above which thereʼs an increased risk of infertility, does not exist, as it does 
exist for BMI (Ho-Pham et al., 2011) and WC as a surrogate marker for central 
obesity ignores the differences in body height. Next to WC, WHtR has the 
advantage of taking into account the WC as well as height, which avoids some 
of the problems regarding the measuring of body composition (Ashwell, 2011; 
Ashwell & Gibson, 2016). The Ashwell Shape Chart figures out that each 
additional 4 cm of height allows to raise the waistline by 2 cm while keeping 
WHtR unchanged. 
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However, even if the weight gain affects fertility potential the negative effect 




8.4. The relationship between metabolic syndrome and 
semen quality 
Abdominal obesity is also an integrated part of MS. Despite our findings, which 
demonstrated that central adiposity correlates negatively with sperm parameters, 
we failed to show associations between MS and semen analysis, even in the 
MPIC group where the prevalence of MS was significantly higher (17.8%) than 
in the FM group (12.2%). It could be that the clinical manifestation of MS vary 
between age groups and a combination of certain components of MS and/or the 
combination of MS with some other factors plays a role. Although we did not 
find an independent relationship between semen quality and MS within BMI 
categories, based on our preliminary findings, differences in glycose and insulin 
levels seem to be interesting in the context of MS and reproductive health. We 
found significantly higher fasting glucose and insulin levels in MPIC-MS+ com-
pared to MPIC-MS-. In addition, among MPIC-MS+ over 50% of men had 
higher fasting glucose levels compared to 10.3 % of men among FM-MS+. 
Pitteloud et al., 2005 suggested that Leydig cell steroidogenesis is impaired in 
insulin-resistant states such as obesity and Leisegang et al. (2014) proposed that 
hyperinsulinemia is associated with increased seminal insulin concentrations, 




8.5. The relationships between body composition,  
liver tests and semen quality 
Nevertheless, obesity alone may not be a sufficient cause for decline in semen 
quality. Earlier studies have found that BMI, WC and visceral fat mass are 
associated with liver enzyme levels (Adams et al., 2008; Verrijken et al., 2010). 
We confirmed the results of previous reports showing a positive relationship 
between BMI, WC and liver tests (ALT, GGT) but, more importantly, our 
analysis revealed that in FM, GGT was negatively related to sperm con-
centration and total sperm count. GGT is expressed in a number of tissues 
including many cells within the male reproductive system like the Sertoli and 
the Leydig cells, the epithelium lining the epididymis, seminal vesicle and vas 
deferens (Hanigan & Frierson, 1996). As a cell surface glycoprotein GGT is 
involved in antioxidant defense regulating cellular glutathione (GSH) and 
cysteine homeostasis. On the other hand prooxidant species (superoxide, H2O2, 
thiyl radicals) are produced during GSH catabolism in selected conditions, 
particularly in the presence of iron and copper (Whitfielda, 2001; Paolicchi et 
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al., 2002; Dominici et al., 2003). Depending on circumstances both anti- and 
pro-oxidant status could be true. According to studies alcohol consumption has 
been shown to elevate the indices of iron stores (Whitfieldb et al., 2001; Ioannou 
et al., 2004; Lieb et al., 2011). Furthermore, it is well known that both iron and 
alcohol individually cause oxidative stress and that alcoholics have a com-
promised antioxidant defense system (Singh et al., 2013; Grasselli et al., 2014). 
Seemingly, the pathological effects of elevated GGT is leading to the pro-
duction of highly reactive compounds. Potentially harmful effects of GGT, 
leading to pro-oxidant species formation, could be a possible cause of semen 
decline. In our study, a significant decline in sperm count and concentration 
appeared when GGT levels exceeded 35.5 U/L. It has been proposed that 
elevated serum ALT and GGT levels are independent markers of the activation 
of systemic inflammation and increased oxidative stress (Yamada et al., 2006). 
Unlike GGT ALT is not expressed in male reproductive system although it is 
widely distributed serving as an important contributor to gluconeogenesis and 
amino acid metabolism (Lindblom et al., 2007; Liu et al., 2014). Due to the 
differences between GGT and ALT impact in an organism or some other undis-




8.6. Alcohol consumption in relation  
to body composition, GGT and  
semen quality 
GGT is well known to be related to alcohol use and as predicted, alcohol use 
was related to GGT also in our study. Troublesome drinking patterns as well as 
increasing rates of overweight and obesity are widespread problems in Estonia. 
In 2016, the alcohol consumption was 9.9 litres per capita (aged 15 and over in 
100% alcohol) and was higher among men than among women (Orro E et al., 
2017). The evidence suggests that alcohol leads to overconsumption of energy, 
increasing especially consumption of high-fat savoury foods (Schrieks et al., 
2015; Downer et al., 2017). Therefore, drinking alcohol can lead to weight gain 
(Lukasiewicz et al., 2005; Downer et al., 2017). Our results indicate that 
consumption of alcohol, especially above moderate levels (≥ 16 units/week) can 
be a risk factor for central obesity that may contribute to the problem of fertility. 
Interestingly, raise in BMI increases the effect of alcohol consumption on serum 
liver enzyme activities (Ruhl & Everhart, 2005; Alatalo et al., 2008). 
Seeing the interaction between semen parameters and GGT, we were 
interested in finding out whether the alcohol use could also related to sperm 
quality. Concentrating on GGT activity, we found a negative relationship 
between total sperm count, sperm concentration and alcohol consumption in 
cases with elevated GGT. The decline in semen quality supposedly occurs not 
due to the amount of alcohol consumed but due to the alcohol use accompanied 
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by increased GGT activity. Thereby it might be that even moderate drinking 
could negatively impact semen parameters when the GGT activity increases. As 
regards influence of alcohol consumption on serum GGT activity aging also 
appears to play a role and therefore render individuals more susceptible to 
oxidative stress and ethanol-induced health problems (Tynjälä et al., 2012; 
Danielsson et al., 2013). Danielsson et al. (2013) showed that in men over 40 
years of age, GGT levels appeared to increase with alcohol consumption which 
were only about half of those found in the age group below 40. The mean age of 
our participants was 32.3 year which allows us to presume that there may be 
even bigger decline in total sperm count and sperm concentration as men grow 
older continuing to drink alcohol. 
The relationship between tissue GGT activity and serum GGT activity 
remains yet unsettled but it has been proposed that subfractionating GGT will 
be critical in future determinations of the organ-specific mechanisms respon-
sible for increases in serum GGT activity (Bradley R, 2012). 
In addition, Rastrelli et al., 2013 have shown a positive relationship between 
greater alcohol consumption, smoking and the TTV. Our study confirmed a 
positive association between greater alcohol consumption and a larger TTV. 
Also, men with larger testicles were more abdominally obese. Besides, animals 
with a larger TTV are considered more promiscuous (Harcourt et al., 1981; 
Short, 1997). Taking into account the aforementioned behaviour patterns, it can 
be assumed that men with a larger TTV may be more prone to lifestyle and diet 
patterns that favour becoming overweight. It is likely that genetic factors also 
play a role. 
Altogether, the diagnosis of male factor infertility should no longer be 
regarded only as a fertility concern because semen quality has also been 
suggested as a strong biomarker of general health (Latif et al., 2017). Figure 4 
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We showed that MS and adiposity markers were inversely associated with 
serum levels of total testosterone and SHBG (in FM) but not with oestradiol. 
Even if obesity may be associated more with peripheral conversion of androgen 
to oestrogen, it has been suggested that plasma concentrations of oestradiol 
can’t increase in case of absence of the substrate, testosterone because oestra-
diol levels are directly related to testosterone levels (Dhindsa et al., 2011). 
Moreover, Rohrmann et al. (2011) proposed that one reason for differences 
among studies might be that researchers didn’t take into account testosterone 
and SHBG levels as confounding factors.  
Weight gain associated with lower testosterone levels could be combined 
with increased levels of gonadotropins, but this was not observed. As explained 
by Teerds K et al. (2011) in general, changes in steroid hormone levels com-
pensate for each other, resulting in normal (unaffected) FSH and LH levels in 
most overweight and obese subjects (Teerds et al., 2011). The latter approach 
may also be one possible explanation for our study results. Otherwise, results 
from the European Male Aging Study supported the hypothesis according to 
which obesity associated hypothalamic-pituitary dysregulation blunts gonado-
tropins rise which cannot be compensated by physiological mechanisms (Wu et 
al., 2008; Tajar et al., 2010). Therefore, it is possible that an increase in body-
weight accompanied by other changes in the body (secretion of cytokines and 
adipokines, sleep apnoea, alterations in hormonal balance, oxidative stress, etc.) 
prevent an increase in gonadotropins levels. It has been stated that blocked 
normal physiological reaction to counterbalance testosterone decrease could 
have a longer term negative effect on the male fertility potential (Fui et al., 
2014). In our study we found lower levels of LH seen only in MPIC-MS+ 
compared to MPIC-MS-- group. Glucose and insulin metabolism are believed to 
influence gonadotropins and GnRH neurons can be directly modulated by 
insulin (Salvi et al., 2006). Based on this, obesity related insulin resistance can 
result in subnormal secretion of GnRH which in turn diminishes secretion of 
LH and FSH. Previous studies have shown that low testosterone levels in 
diabetic men are associated with low serum LH (Dhindsa et al., 2004; Maneesh 
et al., 2006). Costanzo et al., (2014) hypothesized that impairment of hypo-
thalamic activity appears in diabetic because of the inhibitory effect of hyper-
glycemia and insulin resistance (Costanzo et al., 2014). Chosich et al., (2017) 
recently showed that hyperinsulinemia combined with elevated lipids suppres-
ses LH and FSH and neither lipids nor insulin have this effect on their own 
(Chosich et al., 2017).  
GGT and ALT levels were not related to reproductive hormones. Neither did 
we find associations between alcohol intake and serum sex-hormone levels.  
This study had some limitations. A major limitation of our research (in 
MPIC) can be the lack of SHBG for calculation because it is well known that 
obesity and MS are associated with the reduction of SHBG levels. Also, our 
ANCOVA analysis was restricted by missing information regarding lifestyle 
parameters. Moreover, there is mounting evidence that beside the traditional 
WHO sperm parameters, the mechanisms inducing changes to sperm molecular 
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composition are equally important measures of obesity-related male subfertility 
and may provide additional information, which is lacking in current study. 
Despite these limitations, the study had also several strengths. Analysing and 
comparing data from different subgroups of men (FM and MPIC) certainly gave 
us a more comprehensive view concerning male reproductive health. In addi-
tion, using different surrogate measures of adiposity provided a more thorough 
understanding of the relationship between obesity and male infertility. 
Further perspectives: to continue to find out what is the best body composi-
tion marker, showing most clearly the relationships between adiposity and 
reproductive parameters, to determine the factor or combination of factors of 
MS that contribute mainly to male infertility and to go forward with research on 




1. MPIC were more affected by adiposity, especially by abdominal obesity. 
60.4 % of MPIC were overweight or obese compared to 51.2% of FM. High 
risk WC (≥ 102 cm) was found in 26.1% of MPIC compared to 14.6% of 
FM. High risk WHtR (> 0.5) was found in 57.8% of MPIC compared to 
47.7% of FM. Compared to the general population less overweight and 
obese men were found in the FM group. The prevalence of overweight and 
obesity was almost comparable between men in the general population and 
in the MPIC group. 
 Moreover, 17.8% of MPIC had obesity-associated MS compared to 12.2% of 
FM of the same age range. At the same time, the prevalence of MS among 
men in the general population was higher compared with our results. 
2. Adiposity, especially abdominal obesity, was associated with decline in 
semen parameters. The negative effect of adiposity became noticeable in the 
highest quartile of WC, WHtR, BF% and BMI. Among FM, high WC, 
WHtR and BF%, were negatively associated with total sperm count. The 
BF% was also negatively related to semen volume. These changes appeared 
from a WC > 98 cm, WHtR > 0.54 and BF% ≥ 23.4 %.  
 In MPIC clear differences in semen quality appeared from a WC ≥ 102 cm, 
WHtR ≥ 0.56 and BMI ≥ 29.1 and men with smaller testicles (TTV≤ 46 ml) 
were more affected by changes in body composition. In the case of a TTV  
≤ 46 ml all three measures were negatively associated with the total sperm 
count and the sperm concentration. 
 Next to these changes MS had no independent effect on major fertility 
parameters in different subgroups of men. 
3. Adiposity and MS were associated with decline in hormonal parameters. In 
both groups (FM and MPIC) adiposity markers and MS were negatively 
correlated to the total testosterone levels. Likewise, negative correlation was 
found between adiposity markers and SHBG in FM. Adiposity markers were 
not related to oestradiol and gonadotropin levels. Similarly, FSH as well as 
oestradiol levels were not related to MS. LH was negatively correlated to 
MS but only in MPIC. 
5. GGT was negatively related to sperm concentration and total sperm count. 
These changes appeared from a GGT >35.5 U/L. ALT was not related to 
sperm parameters. GGT and ALT were not related to reproductive hor-
mones. 
6. In both groups (FM and MPIC) alcohol consumption was positively cor-
related to adiposity parameters (BMI, WC, WHtR). In FM, alcohol 
4. Next to BMI, there were more informative measures of central obesity and 
adiposity as indicators of male reproductive health. In FM, semen quality 
was most strongly correlated with WC and BF%. In MPIC, WHtR seemed to 
be more predictive surrogate measure of adiposity in the association between 
TTV and male reproductive function. 
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consumption was positively correlated to GGT. Alcohol consumption 
together with elevated GGT (> 60 U/L) was negatively related to total sperm 
count and sperm concentration. Abnormal liver tests, related to alcohol con-




10. SUMMARY IN ESTONIAN 
Kehakompositsiooni, rasvumise ja rasvumisega seotud  
eluviisi ning tervisenäitajate seosed mehe 
reproduktiivfunktsiooniga 
Probleemid laste saamisel toovad iga-aastaselt uuringutele üha enam paare. 
Hinnanguliselt ei suuda aasta jooksul saavutada soovitud rasestumist ligi viis-
teist protsenti viljakas eas paaridest. Neist pooltel juhtudel osutavad muutused 
viljakusnäitajates mehega seotud teguritele. Viljakusprobleemidega paaride 
arvu tõusu põhjuste osas arenenud riikides puudub küll konsensus, kuid oma 
rolli mängib kindlasti nii ema kui isa ühe kõrgem vanus laste sünnil.  
On teada, et viimase sajandi vältel on meeste spermakvaliteet olulisel määral 
langenud (Carlsen et al., 1992, Levine et al., 2017). Viljakusnäitajate võimaliku 
halvenemise põhjusena nähakse mitmete teiste tegurite kõrval kiirelt muutunud 
eluviise. Isegi kui puudub ühtne arusaam langenud viljakusnäitajate seostest 
eluviisiga, näivad osad faktorid omavat suuremat mõju. Olemasolevad uuringud 
kinnitavad, et teisenenud liikumis- ja toitumisharjumused ei ole jäänud taga-
järgedeta. Paralleelselt mehepoolsete viljakusprobleemide kasvuga on pea 
kolmekordistunud viljakas eas olevate ülekaaluliste meeste osakaal (Palmer et 
al., 2012). 2017. aasta Eesti täiskasvanud rahvastiku tervisekäitumise uuringu 
andmetel oli 59.9 protsenti meie meestest ülekaalulised, kellest rasvunuks 
hinnati 19.8 protsenti (Tekkel M, 2017). Võttes arvesse kõiki vanusegruppe, 
avaldub ülekaalulisus varem ning on arvuliselt suurem just meeste hulgas. On 
uuringuid, mis seostavad rasvumist mehepoolse viljakusvõime langusega 
(Jensen et al., 2004; Travison et al., 2007; Hammoud et al., 2008; Hofny et al., 
2010, Paasch et al., 2010; Hammiche et al., 2012; Eisenberg et al., 2014; 
Leisegang etal., 2014; Tsao et al., 2015), kui ka neid, mis ei näe kaalutõusu ja 
viljakusparameetrite vahel olulisi seoseid (Aggerholm et al, 2008; Li et al., 
2009; Duits et al., 2010, Macdonald et al., 2013; Lu et al., 2014). Küll ollakse 
pea ühiselt nõus, et ülekaal mõjutab hormonaalset tasakaalu. Eelkõige seondub 
liigne kehakaal meestel testosterooni taseme langusega, mida peetakse oma-
korda üheks viljakuse languse põhjuseks (Jensen et al., 2004; Fejes et al. 2005; 
Aggerholm et al., 2008; Wu et al., 2008; Chavarro et al., 2010; Rohrmann et al., 
2011 MacDonald et al., 2013; Lu JC, 2014). Kuna metaboolse sündroomi (MS) 
keskseks komponendiks on vööpiirkonna rasvumine, on antud teemale viljakus-
uuringutes samuti üha enam tähelepanu pööratud. Uuringuid, mis aga kinni-
taksid MS otsest negatiivset mõju spermakvaliteedile, on siiski vähe (Lotti et 
al., 2013; Leisegang et al., 2014 et al; Ventimiglia et al., 2016b; Elsamanoudy et 
al., 2016).  
Kuigi uuringutes on kehakompositsiooni iseloomustamiseks enim kasutatud 
kehamassi indeksit (KMI) ei võimalda see hinnata lihasmassi ja rasvkoe osa-
kaalu ning rasvkoe paiknemist kehas. KMI alusel võib normaalse rasvamassi, 
kuid samas suurema lihasmassiga isik sattuda ülekaaluliste klassi ning aine-
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vahetuslikus mõttes rasvunud normkaaluline jääda märkamata (Ruderman et al., 
1981; Cabler et al., 2010). Kehakompositsiooni hindamisel KMI-d ainupara-
meetrina kasutades jäävad toodud eripärad seega tähelepanuta. Kuna tervise-
riskidega on enam seotud vööpiirkonna rasvahulga tõus, tuleks KMI kõrval 
võtta arvesse vööümbermõõtu (VÜ). Maailma Tervishoiuorganisatsiooni 
kohaselt on kaukaasia rassist meestel (sh. eestlastel) VÜ ≥ 102 cm seotud kõrge 
ja VÜ > 94 cm suurenenud riskidega tervisele (Alberti et al., 2009). Suhteliselt 
uue, aga käepärase antropomeetrilise näitajana on kasutusele võetud vööümber-
mõõdu- pikkuse suhe (VÜ/Pi), mis võtab vööümbermõõtu hinnates arvesse ka 
inimese kasvu (Browning et al, 2010). Lubatud referentside kohaselt ei tohiks 
antud suhe olla suurem kui 0.5 ehk madala riskiga tervisele on vöökoht, mis 
mõõdetuna on pool või alla poole meie pikkusest.  
Meeste viljakust hinnatakse põhiliselt seemnevedeliku analüüsi alusel. 
Samas on viljakuspotentsiaali hindamise üheks lihtsamaks meetodiks munandi-
mahttude (MM) määramine. Kriitilist MM väärtust, mis tagaks adekvaatse 
reproduktiiv-funktsiooni, pole siiani aga kindlalt määratletud. Uringute põhjal 
on soovituslik optimaalne munandi maht küllalt laiapiiriline, jäädes vahemikku 
14–35 ml (Takihara et al., 1983; Jørgensen et al., 2002; Sakamoto et al., 2008; 
Stewart et al., 2009; Nieschlag et al., 2010; Andrology Australia, 2014). Eelne-
valt on mehe viljakusparameetrite ja MM vahelisi positiivseid seoseid kinni-
tanud mitmed uuringud (Sakamoto et al., 2008; Bahk et al., 2010; Tijani et al., 




Uurimistöö üldiseks eesmärgiks oli hinnata kehakompositsiooni, ülekaalu ning 
ülekaaluga seonduvate tervisenäitajate ja eluviisi seoseid sperma- ning hormoon 
parameetritega rasedate naiste meestel (RNM) ja viljatute paaride mees-
partneritel (VPM).  
Uurimistöö konkreetsed eesmärgid: 
1 .  Hinnata ülekaalu ja MS levimust RNM ja VPM hulgas. 
2 .  Hinnata erinevate antropomeetriliste näitajate ja MS seoseid sperma 
parameetritega RNM ja VPM grupis. 
3 .  Hinnata erinevate antropomeetriliste näitajate ja MS seoseid reproduktiiv 
hormoonidega RNM ja VPM grupis. 
4 .  Hinnata, milline ülekaaluga seonduv antropomeetriline näitaja toob kõige 
paremini välja võimalikud seosed kehakompositsiooni, rasvumise, sperma 
parameetrite ja reproduktiiv hormoonide vahel. 
5 .  Hinnata maksaensüümide (GGT, ALT) seoseid viljakusparameetritega RNM 
grupis.  
6 .  Hinnata alkoholitarvitamise mõju kehakompositsioonile (RNM, VPM grup-




Uuritavad ja meetodid 
Mitut keskust kaasav (Tartus ja Tallinnas) läbilõikeuuring viidi läbi aastatel 
2008–2013. RNM uuringugrupi moodustamiseks teavitati uuringust Tartu 
Ülikooli Kliinikumi ja Lääne-Tallinna Keskhaigla naistekliinikutesse pöördu-
nud 3175 raseda naise meest. Oma nõusoleku uurimistöös osalemiseks andis 
ligemale kolmandik teavitatutest. Peale esmast andmete läbivaatust kaasati 277 
meest, kes olid nõustunud lisaks meditsiinilisele läbivaatusele (antropomeetri-
lised näitajad ja MM) andma spermaanalüüsi (WHO 2010) ja vereanalüüsi 
suguhormoonidele (FSH, LH, testosteroon, östradiool, SHBG). Lisaks paluti 
meestel täita küsimustik, mis sisaldas andmeid nii terviseseisundi kui eluviiside 
(sh. alkoholitarbimise ja suitsetamise) kohta. Uuringust eemaldati 17 meest. 
Eemaldamise põhjuseks olid diagnoositud sugutrakti kahjustavad haigused, 
varasemalt teostatud väikevaagna piirkonna operatsioonid, liiga lühike või pikk 
abstinentsi periood (WHO 2010) või juhud, kus rasedus oli saavutatud IVF 
protseduuri abil. Saadud andmete põhjal kaasati antropomeetriliste näitajate ja 
viljakusparameetrite vahelisi seoseid hindavasse uuringusse 260 meest (vanus 
21–57 aastat). Maksaensüümide ja viljakusparameetrite vahelisi seoseid hinda-
vasse uuringusse kaasati 245 meest. Uuringusse võeti mehed, kellel lisaks ülal 
mainitud tervisenäitajatele oli määratud ka maksaensüümide tase (ALT, GGT). 
15 mehel need andmed puudusid. 238 juhul lisandusid andmed vereõhu 
väärtuste ja üldtervise analüüside (paastuglükoos, üld-, LDL- ja HDL- koles-
terool, triglütseriidid) kohta. Antud mehed kaasati metaboolse sündroomi ja 
viljakusparameetrite vahelisi seoseid hindavasse uuringusse. Metaboolse 
sündroomi hindamiseks kasutati Rahvusvahelise Kolesterooli Õppeprogrammi 
Täiskasvanute III Ravipaneeli (NCEP ATP III) kriteeriume. 
VPM uuringugrupp moodustati TÜK meestekliinikusse uuringutele pöördu-
nud patsientide baasil. Uuringusse kaasamise kriteeriumiks oli varasem teada-
olev paariviljatus rohkem kui ühe-aastase perioodi jooksul. Uuritavatel teostati 
meditsiiniline läbivaatus, seemnevedeliku analüüs (WHO 2010) ning võeti 
vereanalüüsid suguhormoonidele (FSH, LH, testosteroon, östradiool) ja üld-
tervise näitajatele (vt. ülal). Lisaks paluti täita terviseküsimustik. Uuringust 
eemaldati alla ühe-aastase paariviljatuse anamneesiga ning aspermia või azoo-
spermiaga mehed ning need, kellel oli diagnoositud kindel viljatusega seonduv 
haigus (sugutrakti arenguhäired, geneetilised põhjused, jm), liiga lühike või 
pikk abstinentsi periood, kes olid üle 50 aasta vanad või kellel puudusid andmed 
antropomeetriliste- hormoon- ja/või üldtervise näitajate kohta. Saadud andmed 
võimaldasid kaasata MM, antropomeetriliste näitajate ja viljakusparameetrite 
vahelisi seoseid hindavasse uuringusse 2672 meest ning metaboolset sündroomi 
ja viljakusparameetrite vahelisi seoseid hindavasse uuringusse 2642 meest. 
Mõlema grupi puhul (RNM ja VPM) kasutati kehakompositsiooni hinda-
misel järgmisi parameetreid: KMI, VÜ, VÜ/Pi. RNM grupi puhul lisandus keha 
rasvaprotsent (RP). Meeste alkoholitarvitamise harjumusi hinnati AUDIT testi 
alusel (Babor TF et. al, 2001). Mehed jagati alkoholitarbimise kogustest 
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lähtuvalt kolme gruppi arvestades üheks alkoholiühikuks 10 g puhast alkoholi 
(mitte-tarbijad, < 16 ühiku/ nädalas, ≥ 16 ühiku/ nädalas). 
Statistilises analüüsis kasutati tarkvarapaketti SPSS Windows 20.0 (SPSS 
Inc. Chicago, IL). Lubatud statistilise vea piiriks valiti 5% (p<0.05).  
Uuringus osalemine oli vabatahtlik. Uuring oli eelnevalt heaks kiidetud 
Tartu Ülikooli Inimuuringute Eetikakomitee poolt (eetika komitee protokoll No 
152/4, 2006 ja protokoll No 188/M-16, 2009). 
 
 
Uurimistöö tulemused ja järeldused 
Meie uurimistöö täiendas seniseid teadmisi ülekaalu ning ülekaaluga seondu-
vate tervisenäitajate ja eluviisi mõjust mehe reproduktiivfunktsioonile.  
1 .  Võrreldes RNM grupiga avaldusid ülekaal ja rasvumine, eelkõige vööpiir-
konna rasvumine, suuremal määral VPM grupis. VPM hulgas oli ülekaalulisi 
60.4%, kellest rasvunuks võis lugeda 19.9 %. Samas oli RNM grupis 
ülekaalulisi 51.2 %, kellest rasvunuid 14.7%. VPM grupis esines kõrge riski 
VÜ (≥ 102 cm) 26.1%-l ja kõrge riski VÜ/Pi (> 0.5) 57.8%-l. RNM grupis 
olid vastavad näitajad 14.6% ja 47.7%. Ülekaalu ja rasvumise esinemis-
sagedus VPM grupis oli võrreldav mehi iseloomustavate näitudega üld-
populatsioonis. Ülekaalu ja rasvumise esinemissagedus RNM grupis oli aga 
üldpopulatsiooniga võrreldes madalam. MS esinemissagedus VPM grupis oli 
17.8 % ja RNM grupis 12.2 %. Saadud tulemused olid madalamad võrreldes 
MS esinemissagedusega üldpopulatsiooni meeste hulgas. 
2 .  Vööpiirkonna rasvumine seondus uuritavatel sperma parameetrite langusega. 
RNM grupis esines oluline negatiivne seos antropomeetriliste näitajate (VÜ, 
RP, VÜ/Pi) ja spermatosoidide koguarvu ning RP ja sperma mahu vahel. 
Samas ilmnes kaalutõusu ja vööpiirkonna rasvumise negatiivne mõju sperma 
parameetritele alles siis kui RP ≥ 23.4%, VÜ > 98 cm ja VÜ/Pi > 0.54. 
VPM grupi andmeid analüüsides leidsime positiivse seose antropo-
meetriliste- (pikkus, KMI, VÜ, VÜ/Pi) kui ka reproduktiivse funktsiooni 
parameetrite (va. testosterooni tase) ja MM vahel. Uuritavate keskmine 
bilateraalne MM oli 46 ml. Eelduste kohaselt võiks MM kasvades VÜ/Pi 
suhe jääda muutumatuks, kuid nii mõõdetud VÜ kui VÜ/Pi suhe viitavad 
suurema MMga meeste puhul probleemsele rasva kogunemisele vöö piir-
konda. MM tõusuga paralleelselt suurenes ka RP. VPM grupis saadi 
negatiivne seos antropomeetriliste näitajate (KMI, VÜ, VÜ/Pi), MM, sperma 
mahu, spermatosoidide koguarvu ja -kontsentratsiooni vahel. Olulise tulemu-
sena ilmnes, et kaalutõusust ja vööpiirkonna rasvumisest olid enam mõjuta-
tud mehed MMga ≤ 46 ml. Võrreldavalt RNM grupiga ilmnesid siingi 
muutused alles tugevalt väljendunud kehakompositsiooni muutuste ja kaalu-
tõusu puhul: KMI ≥ 29.1, VÜ ≥ 102 cm, VÜ/Pi ≥ 0.56. Arvestades saadud 
tulemusi oleks kehakaalu tõusust tulenevaid viljakust mõjutavaid riske 
kaaludes vaja kõrvuti kehakompositsiooniga hinnata ka MM.  
MS ja sperma näitajate vahel seoseid ei leitud (RNM, VPM grupis). 
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3 .  Kehakompositsiooni parameetrid seondusid negatiivselt testosterooni (RNM, 
VPM grupis) ja SHBG tasemega (RNM grupis), kuid mitte teiste sugu-
hormoonidega (RNM, VPM grupis).  
Kolm kehakompositsiooni parameetrit seondusid negatiivselt testosterooni 
tasemega, kuid sarnaselt RNM grupiga, puudus seos teiste suguhormoo-
nidega. MS esinemise korral leiti negatiivne seos testosterooni tasemega 
(RNM, VPM grupis). VPM grupis leiti negatiivne seos ka MS ja LH taseme 
vahel. 
5 .  Uuringu tulemused kinnitasid varasemat teadmist positiivsest seosest kaalu-
tõusu ja maksaensüümide (ALT, GGT) taseme vahel. Teadaolevalt näitasime 
aga esmakordselt seoseid viljakuse languse ja GGT taseme vahel (RNM 
grupil). Meie uuringus seondus GGT taseme tõus > 35.5 U/L spermato-
soidide koguarvu ja -kontsentratsiooni olulise langusega. ALT tõus sperma 
näitajatele mõju ei avaldanud. Samuti ei leidnud me seoseid ALT, GGT ja 
suguhormoonide taseme vahel. 
6 .  Lähtuvalt kogustest oli alkoholitarbimine mõlemas grupis (RNM, VPM) 
seotud kaalutõusu ja vööpiirkonna rasvumisega (KMI, VÜ ja VÜ/Pi alusel). 
Lisaks saime positiivse seose alkoholitarbimise ja bilateraalse MM kui 
alkoholitarbimise ja MS esinemise vahel. 
RNM grupilt saadud andmete kohaselt seondus alkoholitarbimine posi-
tiivselt GGT tõusuga, kuid analüüsi tulemuste põhjal puudus alkoholitarbi-
misel eraldiseisvalt mõju spermanäitajatele. GGT taseme tõus (> 60 U/L) 
koos alkoholitarvitamisega oli aga seotud spermatosoidide koguarvu ning –
kontsentratsiooni langusega. Hormoonnäitajate, alkoholitarbimise ja maksa-
ensüümide tõusu vahel seoseid ei avaldunud. 
 
  
4 .  Kehakaalu ja vööpiirkonna rasvumist iseloomustavate antropomeetriline 
näitajate puhul täheldati, et KMI kõrval leidub teisi parameetreid, mis toovad 
selgemini esile seosed kehakompositsiooni, rasvumise, sperma parameetrite 
ja reproduktiiv hormoonide vahel. RNM grupis ilmnesid kõige tugevamad 
seosed viljakusparameetrite ning VÜ ja RP vahel. VPM grupis saadi kõige 
tugevam negatiivne seos viljakusparameetrite ja VÜ/Pi vahel.  
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